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ABSTRACT 
 
Repressor of Estrogen Receptor Activity (REA) is an evolutionarily conserved protein 
with established roles in multiple, essential cellular processes including transcription, 
mitochondrial biogenesis and replicative senescence. Previous reports suggest that REA is a 
multifunctional protein with important biological activity. However, despite increasing 
information, the physiological functions and regulatory mechanisms of REA are still 
incompletely understood. To gain insight into the role of REA in estrogen responsive tissues, we 
investigated its function in both the uterus and mammary gland by conditional deletion of the 
REA gene, because the conventional knockout of REA is embryonic lethal. To this end, we 
generated REA
f/f 
mice and crossed them with PR-Cre knock-in mice as well as WAP-Cre 
transgenic mice, thereby creating conditional REA knockouts under the control of either the 
progesterone receptor or whey acidic protein promoter. We found that complete REA loss of 
function resulted in severe defects in both uterine and mammary gland development and 
functional activities. REA deletion in the uterus resulted in infertility due to severely 
compromised uterine development and function. Ablation of REA in the mammary gland 
resulted in impaired mammary gland ductal and alveolar morphogenesis, leading to reduced 
body size and growth of the offspring nursed by females lacking both REA alleles. These 
observations demonstrate that REA is critical for normal uterine and mammary gland function. 
By contrast, 50% reduction of REA via heterozygous inactivation enhanced estradiol (E2) 
response in both the uterus and mammary gland. Heterozygous REA mutant mice treated with 
E2 developed abnormally large uteri due to increased E2-mediated uterine epithelial cell 
proliferation and increased fluid imbibition. Additionally, mammary ductal elongation during 
puberty was accelerated in heterozygous mice. Our findings indicate that REA possesses dose-
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dependent activity, showing a positive modulatory role in heterozygous REA animals and a 
negative modulatory role in homozygous REA animals. These studies in animals with 
conditional loss of both or only one allele of REA highlight the importance of the correct gene 
dosage of REA for normal uterine and mammary gland function.  
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CHAPTER 1 
ROLE OF ESTROGEN ACTION IN UTERINE AND MAMMARY GLAND 
PHYSIOLOGY 
 
1.1. INTRODUCTION 
Molecular mechanisms of estrogen action 
The ovarian steroid hormone estrogen (E) is a key modulator of normal mammalian 
reproductive functions. It profoundly impacts the growth and development of female 
reproductive organs such as the uterus, ovary and mammary gland (8, 19).  
The biological effects of estrogen are mediated through the estrogen receptor (ER) 
proteins which bind the hormones, dimerize, and regulate the transcription of estrogen-
responsive genes. ER exist as two isoforms, ERα and ERβ, which are members of the nuclear 
receptor superfamily of ligand-activated transcription factors (22, 44). Although these two 
subtypes of ER differ with respect to tissue distribution and functional activities, both isoforms 
share a similar structure (28, 40). ERs contain an N-terminal activation function (AF-1), a DNA 
binding domain (DBD), and a C-terminal activation function (AF-2) which contains the ligand-
binding domain (LBD) (12).  
Although there are several proposed mechanisms of ER action, traditionally, two main 
categories are designated, namely, classical or genomic pathway and non-genomic pathway.  In 
the classical mechanism of ER action, upon hormone stimulation, ERs dissociate from chaperone 
protein, dimerize, and bind to DNA sequences known as estrogen response elements (EREs) 
which are located in the promoters of target genes (40). Estrogen-dependent transcriptional 
regulation through ERE pathway involves a variety cofactors that function with liganded ERs to 
modify histones, alter chromatin structures, and recruit the RNA polymerase II (polII) 
transcriptional machinery (24). Many coactivators bind directly to agonist-activated AF-2 of ER 
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through short α-helical “LXXLL” motifs called NR boxes (14, 52). Coactivators include 
following: (1) histone-modifying enzymes complexes that contain number of the steroid receptor 
coactivator (SRC) family of proteins, (2) chromatin remodeling complexes such as SWI/SNF, 
and (3) mediater complexes such as TRAP and DRIP (52).  
It is known that approximately one third of ER-regulated genes do not contain EREs in 
the promoters (43). These genes are regulated by ERE-independent genomic mechanism by 
which ER indirectly binds to other response elements through interactions with other 
transcription factors including activating protein 1 (AP1), stimulating protein 1 (SP1), or NF-κB 
(43, 51, 54).  
Estrogen can also exert its effects through very rapid non-genomic mechanisms and are 
believed to be mediated through extranuclear ER. This mechanism is frequently associated with 
the activation of protein kinase cascades: phospholipase C (PLC)/protein kinase C (PKCs), 
Ras/Raf/MAPK, phosphatidyl inositol 3 kinase (PI3K)/AKT and cAMP/ protein kinase A (PKA) 
(11, 29, 31).  
 
The role of estrogen action in uterine functions 
The uterus is a major estrogen-responsive organ and plays a central role in female 
reproduction. During the proliferative phase of the menstrual cycle, 17β-estradiol (E2) stimulates 
the rapid growth of the uterine endometrium, including both epithelial and stromal cells (48). In 
rodents, the uterus responds to cyclical changes in estrogen and progesterone levels for 
preparation of implantation and for pregnancy to be established and maintained (18, 19, 42). 
During pro-estrous stage, a surge in the blood estrogen concentration results in the well 
characterized physiological and biochemical changes of the uterus. These responses have been 
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divided into two events that occur early, within the first hours after E2 surges, and subsequent 
responses that follow up to 24 h after E2 elevation (18, 33). Early uterine responses to estrogen 
include estrogen receptor occupancy, transcription of early phase genes such as c-fos, water 
imbibition, hyperemia, eosinophil infiltration, and calcium influx. The later phase responses 
include the transcription of late phase genes such as lactoferrin, increase in uterine wet weight, 
futher accumulation of immune system cells, the development of the epithelial layer into 
columnar secretory epithelial cells, cellular
 
hypertrophy and hyperplasia, resulting in growth of
 
the uterus (18, 55). These physiological effects of estrogen in the uterus are mediated via its 
cognitive nuclear receptor, estrogen receptor alpha (ERα) (8).  In the mouse uterus, ERα 
expression begins to appear in the stroma on postnatal day (P) 1 and is detectable maximally on 
P10, whereas the expression of epithelial ERα is delayed and reaches a peak around P16. Thus, a 
full biological response to estrogen in terms of maximum increases in uterine weight is not 
possible until at least postnatal day 16, and can be observed only after the animal approaches 
weaning age (P19-21) (8, 57).  
The role of ERα in normal uterine function was largely elucidated through knockout of 
ERα (αERKO) in mice. The αERKO mice have hypoplastic uteri but contain all three definitive 
uterine compartments, the outer myometrium, endometrial stroma, and epithelium. However, the 
uteri have a reduced proportion of stroma, with a sparse distribution of uterine glands (23). This 
suggests that ERα expression may not be essential for uterine organogenesis itself, but it is 
required for normal uterine growth and maturation.   
  Estrogens also play a particularly critical role at the time of implantation. There is a 
limited time period, so called the window of implantation, when the uterus becomes favorable to 
blastocyst acceptance and implantation (30). In mice, the uterus becomes receptive on day 4 of 
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pregnancy and proceeds to the refractory state on day 5 (46). Estrogen levels within a very 
narrow range determine the duration of this window of uterine receptivity. It has been shown that 
this period of uterine receptivity shortens greatly if estrogen levels exceed this narrow range, 
because higher estrogen levels induce a refractory state of the uterus that is accompanied by 
aberrant expression of implantation-related genes (30).  
 
Estrogen regulation of mammary gland development 
The mammary gland is a specialized organ of female mammals, which enables them to 
supply their offspring with all essential nutrients via the milk produced in the gland. Two main 
compartments constitute the mammary gland: the epithelium, which consists of ducts and 
alveolar cells; and the stroma, which is also called the mammary fat pad. Each fat pad has an 
exterior nipple to which the primary epithelial duct is connected to allow the release of milk 
during lactation and at least one major lymph node (15, 49).  
The majority of mammary gland development takes place postnatally beginning with the 
onset of puberty and remains undifferentiated until pregnancy and lactation (8, 15, 49). 
Development of the mammary gland is divided into five distinct stages: embryonic, pre-pubertal, 
pubertal, mature adult and pregnancy/lactation. Each developmental stage is tightly regulated by 
an orchestration of ovarian steroid hormone and growth factor action (4, 15, 26, 49). Throughout 
the recurrent estrous cycles, the epithelial ductal network and branching increase, while in 
pregnancy and lactation, alveolar units proliferate and differentiate into milk-secretory cells (15, 
16). The ovarian steroid hormones, estrogen and progesterone, are key mediators of ductal 
morphogenesis and are mitogenic for mammary epithelial cells (15). These physiological effects 
of hormones are mediated through the estrogen receptor (ER) and progesterone receptor (PR), 
both members of the nuclear receptor superfamily of ligand-activated transcription factors (22).  
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Of the two estrogen receptors (ERα and ERβ), ERα is believed to be the primary receptor for 
mammary gland development and function.  
After birth and until puberty, the mammary gland remains rudimentary. At onset of 
puberty, the mammary gland develops rapidly in response to changes in circulating hormone 
levels (16, 49). Ductal elongation during puberty occurs through cap cell proliferation at the 
terminal end buds (TEBs) of each individual duct, while maintaining close contact with the 
stromal fat pad. Estrogen has been shown to directly stimulate the formation of TEBs and 
promote proliferation of the mammary ductal epithelium (8, 9). However , the outermost 
proliferating cap cells do not express ER, suggesting the existence of indirect estrogen action in 
mammary gland development (8, 9). More recently, the Brisken lab performed a series of 
transplantation experiments to demonstrate that estrogen facilitates epithelial proliferation and 
morphogenesis through a paracrine mechanism (32). When ERα-null epithelial cells were mixed 
with the wild-type epithelial cells and transplanted into the cleared fat pads of wild-type mice, 
ERα-null epithelial cells proliferated when wild-type cells were in close proximity, suggesting 
that paracrine factors secreted by neighboring cells induce proliferation of ERα-negative 
epithelial cells (32). Several paracrine factors are known to regulate hormone-induced 
proliferation and morphogenesis including Wnt-4, receptor activator of NF-κB ligand (RANKL), 
growth hormone and insulin growth factor ΙΙ (53). With regard to estrogen action, amphiregulin 
(AREG), a member of the epidermal growth factor receptor (EGFR) family of ligands that binds 
exclusively to ErbB1, is known to be the major paracrine mediator of ductal morphogenesis (7, 
26).  
The role of ERα in mammary gland development was also largely elucidated through 
αERKO mice. Mammary glands of αERKO mice were normal before puberty, however, after the 
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onset of puberty, a rudimentary ductal structure remained and the ducts failed to invade the 
mammary fat pad (8). More recently, Khan and colleagues developed whey acidic protein 
(WAP) driven Cre-mediated conditional ERα knockout mice in an attempt to address the role of 
ERα in mammary gland development during pregnancy and lactation (13). They demonstrated 
that the ablation of ERα in mammary epithelium during late pregnancy and lactation, when the 
alveolar epithelium has begun to differentiate, results in a loss of ductal side-branching and 
lobuloalveolar structures, ductal dilation, and decreased proliferation of alveolar progenitors 
(13). However, the mechanism by which estrogens regulate mammary gland development during 
pregnancy and lactation remains unclear.  
 
The role of coregulators in modulating nuclear receptor-mediated actions 
The state of receptor activation and inhibition is modulated not only by the nature of the 
hormonal ligand but also by a delicate balance between coactivators and corepressors (22, 34).  
Coactivator proteins assemble into several dynamic, multiprotein complexes that constitute the 
SRC/p160 family of proteins, CREB binding protein (CBP) and/or p300, and other factors that 
are recruited in a temporally ordered fashion (6, 34) and up-regulate nuclear receptor activity, at 
least in part, through enhanced histone acetyltransferase activity. ATP-dependent chromatin 
remodeling complexes, such as SWI/SNF, and the TRAP-DRIP-ARC (mediator) complex, 
which act sequentially or combinatorially, also enhance gene transcription by facilitating RNA 
polymerase ΙΙ recruitment to promoters (5, 21, 50, 52). Corepressors act in an opposite manner to 
repress gene transcription, primarily through their interaction with un-liganded nuclear receptors 
or recruitment of histone deacetylases to form a repressive chromatin state (14, 34, 50). Among 
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corepressors, the best fully characterized are NCoR (nuclear receptor corepressor) and SMRT 
(silencing mediator of retinoic acid and thyroid hormone receptor) (50).  
To date, approximately 285 coregulators are reported in the literature, and those are 
frequently associated with numerous physiological functions and pathological conditions (27). 
Development of coregulator knockout animal models has greatly facilitated our understanding of 
their physiological impact at the organism level. Among 285 coregulators, 92 knockout mouse 
models have been documented so far. Of these 92 knockout mice, 53 were embryonic lethal, 
suggesting the overall importance of coregulators  in developmental biology, whereas a wide 
spectrum of phenotypes were observed for others (27). Knockout models of the steroid receptor 
coactivator (SRC) family-SRC-1, SRC-2, and SRC-3-have revealed a great deal about 
coregulator biology in a whole animal context. Knockout of these coregulators results in a wide 
range of defects, including reproductive (uterine and mammary gland) and metabolic defects (27, 
38, 41, 56). Deletion of the corepressor, RIP-140/Nrip-1, resulted in infertility due to anovulation 
and NCoR knockout was embryonic lethal, with defects in erythrocyte and thymocyte production 
and central nervous system defects (17, 27). These knockout animal models demonstrate that 
coregulator proteins are vitally important for normal physiological function, and are also broadly 
implicated in many pathological states and will be of great interest in clinical medicine. 
 
Estrogen receptor-selective corepressor, REA 
ER-selective corepressor REA was previously identified from yeast two-hybrid screening 
through its ability to interact preferentially with the liganded ER, and it was shown to repress ER 
transcriptional activity (37). The REA gene is located in chromosomal region 12p13 in humans 
and chromosome 6 in mice and encodes a 34-kDa protein that is the first ER-selective 
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coregulator to be identified (1, 37). REA interacts directly with ER by in vitro GST pull-down 
assays, and this interaction is hormone dependent (10, 37). REA does not directly affect the 
ability of ER to bind DNA, but rather competes with coactivatiors (SRC-1 or -3), thereby 
interfering with functional coactivator recruitment to ER (10). In addition to binding ER, REA 
has been shown to associate with diverse cellular proteins to regulate transcription such as 
HDAC, a histone deacetylase and the ovalbumin upstream promoter transcription factors Ι and ΙΙ 
(COUP-TFΙ, COUP-TFΙΙ) and enhancer of zeste homolog 2 (EZH2), a chromatin modifying 
polycomb group histone methyltransferase known to be involved in chromatin compaction and 
transcriptional repression (20, 25).  
The regions of REA that is required for interaction with ER, and for its repressive activity 
were previously mapped (10). The regions of REA required for its interaction with ER and for its 
repression of ER activity are different. The repressive activity requires two regions of REA, 
encompassing amino acids 19-49 and 150-174, while REA binds to ligand binding domain (AF-
2) of ER through a region encompassing amino acids 175-198 (10).  
Additionally, REA has also been shown to exist in a complex with prohibitin (PHB), 
which has 50% amino acid sequence identity and 60% similarity, in the mitochondrial inner 
membrane (36). The function of these mitochondrial protein complexes has long been implicated 
in diverse cellular processes such as mitochondrial biogenesis, cell death, and senescence (2, 3, 
35, 45).  
The physiological function of REA as a significant modulator of ER activity in vivo was 
previously established by the conventional REA knockout mouse model. Genetic disruption of 
both alleles of REA (REA
-/-
) resulted in embryonic lethality, suggesting the importance of REA 
in developmental biology. However, REA heterozygous animals (REA
+/-
) with deletion of single 
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REA allele were viable, and exhibited haploinsufficiency that enhanced estrogen function and 
activity in both the uterus and mammary gland (39, 47).  
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CHAPTER 2 
 
COREGULATOR REA GENE DOSAGE IS CRITICAL FOR UTERINE 
DEVELOPMENT AND FERTILITY 
 
2.1. ABSTRACT 
 
Although the effectiveness of hormone-receptor complexes is known to depend on 
coregulator partner proteins, little is known about the roles of coregulators in uterine 
development, early stages of pregnancy, and implantation. Because conventional genetic deletion 
of the coregulator, repressor of estrogen receptor activity (REA) was embryonic lethal, to define 
the roles of REA in post-embryonic stages and in a tissue-specific manner, we have generated 
REA conditional knockout mice by cre-loxP recombination in which REA function was 
abrogated only in progesterone receptor (PR)-expressing tissues. We have examined the role of 
REA in uterine development and functional activities and found that REA shows gene dose-
dependent activity. Conditional homozygous mutant mice (REA
d/d
) developed to adulthood and 
showed normal ovarian function, but females were infertile due to severely compromised uterine 
development and function characterized by cell cycle arrest and apoptosis, resulting in failure of 
implantation and decidualization. By contrast, mice heterozygous for REA (REA
f/d
) had a very 
different phenotype with estradiol treatment resulting in hyperstimulated, abnormally large uteri 
showing increased proliferation of luminal epithelial cells and enhanced water permeability 
associated with up-regulation of aquaporins. Associated with uterine over-stimulation by 
hormone, these heterozygous mice showed a subfertility phenotype with reduced numbers and 
sizes of litters. These findings highlight that REA is a multifunctional protein with key roles in 
uterine development and regulation of estrogen receptor activities required for fertility that are 
distinguishable on the basis of REA’s gene dose-dependent effects.  
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2.2. INTRODUCTION 
Nuclear receptors act as ligand-activated transcription factors mediating the actions of 
many hormones and some non-hormonal ligands. The state of receptor activation and 
suppression is modulated not only by the nature of the ligand but also by delicate balance 
between coactivators and corepressors in a cell (7, 12, 18, 28). Repressor of Estrogen Receptor 
Activity (REA) was initially identified as a coregulator of the Estrogen receptor (ER) that 
repressed the activity of estrogen (32). Our prior conventional genetic disruption of both alleles 
of REA resulted in embryonic lethality (38), suggesting  that REA has fundamentally important 
cellular functions. Interestingly, however, heterozygous (REA
+/-
) animals, which contained one-
half the normal level of REA, developed normally, but their uteri and mammary glands showed 
enhanced responsiveness to estrogen (34, 38), indicating that REA also had a crucial function as 
a modulator of estrogen receptor activity. To be able to address the role of REA in uterine 
development and function, we have generated mice with conditional tissue-selective deletion of 
REA.  
REA, also known as prohibitin 2, is a highly conserved protein (1). In addition to binding 
to the ER, REA has been shown to interact with cellular proteins associated with chromatin 
remodeling and transcriptional repression, such as ovalbumin upstream promoter transcription 
factors I and II (COUP-TFI, COUP-TFII), enhancer of zeste homolog 2 (EZH2), a chromatin 
modifying polycomb group histone methyltransferase and histone deacetylase 1 (HDAC1) (16, 
21, 22), and to compete with coactivators such as steroid receptor coactivator-1 (SRC-1) for 
binding to chromatin of estrogen-regulated genes (32). In addition to its role as a brake on 
estrogen-ER regulated gene expression in the nucleus, REA/PHB2 has also been demonstrated to 
exist in a complex with prohibitin (PHB) in the mitochondrial inner membrane (31), and these 
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mitochondrial protein complexes have been implicated in mitochondrial biogenesis, cell death 
and senescence (2, 29, 31, 37). These findings imply that REA may have pivotal roles in several 
key cellular processes. However, despite accumulating data, the physiological functions that 
REA controls during development remain elusive.  
In the present study, to circumvent the embryonic lethality we encountered in 
conventional knockout mice and to enable the study REA function in post-embryonic tissues, we 
have generated conditional REA knockout mice (REA
d/d
) by cre-loxP recombination in which 
REA function was abrogated only in progesterone receptor (PR)-expressing cell lineages. Our 
findings in animals with conditional loss of both alleles of REA or only one allele of REA 
highlight the importance of the correct gene dosage of REA for optimal uterine development, 
growth and function. Additionally, this knockout mouse model is the first to enable definition of 
the complete loss of REA function phenotype and is also currently the only available model for 
delineating the functional role of REA as a nuclear receptor coregulator in vivo.  
 
2.3. MATERIALS AND METHODS 
Generation of conditional REA knockout mice 
 All animals were maintained in accordance with the NIH Guide for Care and Use of 
Laboratory Animals, and all procedures described here were approved by the University of 
Illinois and Baylor College of Medicine Institutional Animal Care and Use Committees. Adult 
female C57BL mice were purchased from Harlan Co. (Indianapolis, IN).
  
The mouse BAC library clone 284H12 (Invitrogen, Carlsbad, CA) was prepared by 
alkaline lysis method and this DNA was used as the template for mouse REA genomic DNA to 
generate a targeting vector. The targeting vector was designed to flank the REA gene exons 2 
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through 6, which are required for REA repressive activity and for interaction with ER. Two loxP 
sequences were introduced into REA intron1 and intron6. Frt-floxed neomycin-resistance gene 
was inserted between intron 6 and the 5’-loxP site.  The targeting vector contained flanking 5.2 
kb (5'-targeting arm) and 3.0 kb (3'-targeting arm) mouse REA and neighboring sequences for 
homologous recombination. In addition, the herpes simplex virus thymidine kinase (HSV-TK) 
gene was located outside of the REA sequence and served as a negative drug-selection marker. 
The sequence of the targeting vector was verified by a fluorescent dye-terminator sequencing 
method using the BigDye DNA Sequencing Kit (PE Applied Biosystems, Foster City, CA). The 
targeting vector was linearized by I-CeuI digestion and purified by phenol-chloroform extraction 
method for electophoration to ES cells. ES cell work was carried out as previously described (20, 
38).  
Genomic DNAs from selected ES clones were digested with XbaI, followed by Southern 
blotting with 5’ and 3’ probes. The 5' probe for Southern screening was generated by PCR using 
the BAC284H12 (Research Genetics, Inc) clone DNA as a template. A 459 bp 5’ probe was 
generated by PCR of this template using primers 5'- 
CGGAATTCCTATGGACTTGTGTGAGAAGCCG -3' and 5'- 
CGGGATCCCTCAGCCAACCTGGTGATTTTG -3’. In the same way, a 3' probe, 375 bp, was 
generated using primers, 5'-CGGGATCCGCATATATATGTGTGTACTCA-3', and 5'-
CGGGATCCGGGTTACCGTGTGTGTTTAG -3'. Both 3' and 5' probes are designed to detect 
the external region of the targeted locus for selection of the correct insertion. ES cell lines 
showed a 22.4 kb fragment of the wild-type allele, but in targeted cell lines this altered locus was 
detected with 14 kb and 8.4 kb fragments as the result of the introduction of additional XbaI sites 
to the targeting vector (Figure 2.1). ES cells heterozygous for the targeted insertions were 
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microinjected into blastocysts donated from a C57BL/6J strain mouse and implanted into 
pseudopregnant female mice. Male chimeras were mated with C56BL/6J females.  
Genotypes of REA
flox-frt-neo/+
 mice were determined by PCR. For PCR analysis, the 
REA
flox-frt-neo
 allele was detected by primer 1 (P1; 5’-TGGGCTGTCATATTCAAG-3’) and 
primer 2 (P2; 5’-GGTGGGATTAGATAAATGCC-3’), which bind to the neomycin resistant 
cassette of REA
flox-frt-neo
 allele. This primer pair amplifies a fragment 696 bp from the REA
flox-frt-
neo/+
 mice, but not from wild-type mice. DNA was also amplified by using primer 3 (P3; 5’-
CCCAGAACTTGAAGGACTTAGCTG-3’) and primer 4 (P4; 5’-
GAGGTCATGGACAGGAGTTGG-3’) which bind to exon1 and 2, respectively. In this case, a 
743 bp fragment was detected from the REA
flox-frt-neo
 allele and a 611 bp fragment was detected 
from the wild-type allele.  
To generate REA
flox/+
 mice, REA
flox-frt-neo/+
 mice were crossed with mice expressing 
Saccharomyces cerevisiae
 
enhanced FLP1 recombinase variant (FLPe) from the Gt(ROSA)26Sor 
gene (The Jackson
 
Laboratory) to facilitate in vivo frt-neo deletion. Conversion of the REA
flox-frt-
neo/+ 
allele into a REA
flox/+ 
allele was determined by PCR analysis. The REA
flox
 allele was 
detected using primers 3 and 4, which amplify a 743 bp fragment. The REA
WT
 allele was 
detected as a 611 bp fragment after amplification with primers 3 and 4. In addition, primer 5 (P5; 
5’-GCAGGAACAGCGACAGAAGATTG-3’) and 6 (5’-TAGCAGCCCTTGGATGGTGAAG-
3’) for another loxP site were also used for distinguishing REAflox-frt-neo allele and REAWT allele. 
The wild-type allele produced a 495 bp fragment and the REA
flox-frt-neo
 allele yielded a 901 bp 
fragment. The frt-neo deletion by FLP-mediated recombination was confirmed by PCR using 
primers 1 and 2, which amplify a 696 bp fragment from the neomycin resistant gene cassette. In 
this case, no signal was detected in REA
flox/+
 mice. 
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The female REA
flox/+
 mice were mated with the male PR
cre/cre
 knock-in mice (44) to 
generate the REA
flox/+
 PR
cre
 
/+
 bigenic mouse model. To create the REA
flox/flox
 PR
cre
 
/+
 (denoted 
REA
d/d
 ) mice for deletion of the REA gene in both alleles, several pairs of REA
flox/+
 PR
cre
 
/+
 
mice were mated.  
  
Superovulation, implantation and decidualization analyses 
The details of these methods have been previously described (19, 23, 33). Briefly, 
superovulation was induced in 24-day-old mice by administering 5 IU of pregnant mares’ serum 
gonadotropin intraperitoneally (EMD Biosciences, Inc., San Diego, CA), followed by 5 IU 
human chorionic gonadotropin (Sigma-Aldrich Co. St. Louis, MO) given intraperitoneally 48 
hours later. Oocytes were flushed from the oviducts 24 h post human chorionic gonadotropin 
injection and counted.  
Implantation sites at 5.5 days post-coitum (dpc) were visualized by an intravenous 
injection of 1% of Chicago Blue 6B (Sigma-Aldrich Co. St. Louis, MO) dye solution and the 
number of implantation sites was counted.  
To induce decidual reactions, ovariectomized mice were primed with three once daily 
subcutaneous injections of 100 ng of 17β-estradiol (E2). After 2 days rest, mice were treated 
with daily subcutaneous injection of 1 µg of progesterone (P4) and 6.7 ng of E2 in 0.1 mL of 
sesame oil. One uterine horn was mechanically stimulated by an intraluminal injection of 50 µL 
of sesame oil 6 h after the third injection. The right horn was not stimulated. Daily injection of 
P4 and E2 were administered until day 5. Mice were sacrificed at 0 and 2 days after stimulation. 
 
Isolation of uterine stromal cells and induction of decidualization in vitro 
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Uterine stromal cells were isolated as previously described (24, 42). Briefly, uterine 
horns of day 4 pregnant female mice were dissected longitudinally and cut into 5-6 mm pieces. 
The tissues then were washed with Hank’s balanced salt solution (HBSS) and digested with 
dispase (6 g/L) and pancreatin (25 g/L) for 1hr at RT, followed by 10 min at 37°C. The tissue-
digestion mixture was gently mixed, and the luminal epithelial containing supernatant was 
discarded. The partially digested tissues were then washed once in HBSS and re-digested with 
collagenase (0.5 g/L) for 45 min at 37°C.  Digested tissues were mixed until the supernatant 
become turbid with dispersed stromal cells.  The cell suspension was filtered through a 70 µm-
pore-size mesh (BD Biosciences) and centrifuged at 2,000 rpm for 5 min. Cells were then 
resuspended in DMEM-F12 with 2% FBS, and seeded in 6-well culture plate. Isolated uterine 
stromal cells were grown in the medium containing 1 µM P4 and 10 nM E2 for 96 h to induce in 
vitro decidual reactions.  
 
Recombinant Adenovirus preparation 
The Cre-expressing recombinant adenovirus was constructed using an AdEasy XL 
adenoviral vector system kit (Stratagene) according to the manufacturer’s protocols.  Cre coding 
region containing nuclear localization signal (NLS) was amplified from PGK-Cre-bpA plasmids 
(43) obtained from Addgene (Addgene plasmid 115430), and REA coding region was retrieved 
from pCMV-REA (32) and cloned to pShuttle-CMV vector. The pShuttle-CMV-Cre plasmids 
and pShuttle-CMV-REA-Flag were linearlized with PmeI restriction enzyme and then 
transformed into BJ5183-AD-1 cells.  AdEasy-Cre plasmids were selected with PacI enzyme 
after homologous recombination in BJ5183-AD-1 cells. AdEasy-Cre plasmids then were 
amplified, linearized and transfected into human AD-293 cells. After transfection, cells were 
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cultured in DMEM media with 10% FBS until 80-90% of cells were detached from flasks.  
Adenovirus were collected and purified by CsCl gradient protocol as described previously (25).  
Uterine stromal cells were isolated from day 4 pregnant mice and grown as described 
above. 5X10^5 cells were seeded in 6-well plates and cultivated in 5% CO2 for 8 h at 37°C. 
After the cells were allowed to attach for 8 h, the unattached cells were removed by washing 
with HBSS and then incubated with either control adenovirus (AdCMV) or Cre adenovirus 
(AdCre) at different multiplicity of infection (MOI).   
 
Uterine bioassays 
Ovariectomized (8 week of age) or immature (21 day old) female mice were injected 
subcutaneously (s.c.) daily with E2 (0.5 µg/10g of body weight/day) for 4 days. Injections 
consisted of compound dissolved in DMSO and then diluted 1:10 in sesame oil. At 24 h after the 
last injection, animals were sacrificed by carbon dioxide sedation and cervical dislocation. Uteri 
were removed, washed in cold phosphate-buffered saline (PBS), and weighted after removal of 
associated fat and expression of any luminal fluid. One uterine horn from each uterus was stored 
for RNA isolation, and the other horn was fixed for histology. 
 
Histology and immunostaining 
Hematoxylin and eosin staining or immunohistochemistry was performed as previously 
described (19). In brief, the tissues were fixed in 10% buffered formalin phosphate for 24hr at 
room temperature, transferred to 70% ethanol, and then embedded in paraffin. 4 µm sections 
were subjected to hematoxylin and eosin staining or immunostaining using antibodies to REA 
(Millipore Co.), PR (DAKO Co.), p21 (BD Biosciences), or Caspase-3(R&D System).   
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For 5-bromo-2-deoxyuridine (BrdU) incorporation assay, mice were injected 
intraperitoneally with 30 µg/g of body weight BrdU (BD Biosciences, San Jose, CA) 2h prior to 
sacrifice. Uteri were fixed, embedded in paraffin and tissue sections were stained with BrdU 
antibody (BD Biosciences). 
 
Western blot analysis 
Immunoblotting was performed as previously described (38). Uterine stromal cell 
extracts were prepared using ice-cold lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
NP-40, 1%  sodium deoxycholate, 1% SDS) supplemented with protease inhibitors (complete 
EDTA free; Roche, Indianapolis, IN) and phosphatase inhibitors (Phopho-stop; Roche). Protein 
concentrations were determined by the BCA protein assay system (Pierce, Rockford, IL). 
Proteins (20-50 µg) were separated on SDS-PAGE gels, transferred on nitrocellulose membranes 
and subjected to immunoblotting with anti-REA (Millipore, Co., Billerica, MA), anti-Cre 
(Covance Inc., Madison, WI) and anti-β-actin (Sigma-Aldrich, St. Louis, MO).  
 
RNA isolation and real-time PCR 
Total RNA was isolated from whole uterine tissue or uterine stromal cells using Trizol
 
Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. One microgram 
of total RNA was reverse transcribed
 
and analyzed by real-time PCR as described previously 
(38). Primers for the genes studies are as follows: REA forward (f), 
AGTGCTGCCGTCCATTGTTAA; REA reverse (r), TCTTCGGATCAACAGGGACAC; PRPf, 
CCAGCTCATGGACCTGAACAT; PRPr, GGAGTGATCCATGCACCCATA; BMP2f, 
AAAGCGTCAAGCCAAACACA; BMP2r, ACCCCACATCACTGAAGTCCA; Hoxa10f, 
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CACAGGCCACTTCGTGTTCTT; Hoxa10r, TTTGTCCGCAGCATCGTAGAG; Hoxa11f, 
ATTTTGATGAGCGTGGTCCCT; Hoxa11r, AGAAATCTGGACCCGAGACGT; Wnt4f, 
TGCCAATACCAGTTCCGGA; Wnt4r, TCACCACCTTCCCAAAGACAG; VDRf, 
CATCTGCATTGTCTCCCCAGA; VDRr, TTGGATAGGCGGTCCTGAAT; 36B4f, 
CGACCTGGAAGTCCAACTAC; 36B4r, ATCTGCTGCATCTGCTTG; EGFRf, 
TGGATGAAGAGGACATGGAGG; EGFRr, TGGACGGGCTGTTGAAGAA; HGFf, 
GCAAGACAATGTTTTCCAGCC; HGFr, CATGAACATCGTGGATGCCA; p21f, 
TTCCGCACAGGAGCAAAGT; p21r, ATGAGCGCATCGCAATCAC. 
 
TUNEL staining 
Apoptosis was detected by using the In Situ Cell Death Detection Kit (Roche Applied 
Science) according to the manufacturer’s protocol.  Briefly, deparaffinized and rehydrated 
sections were incubated at 37°C for 15 min with 20 µg/mL of proteinase K in 10 mM Tris-HCl 
(pH 7.6). Sections were washed twice with PBS and incubated for 1 h at 37°C with TUNEL 
reaction mixture in a humidified chamber.  After the incubation, sections were rinsed three times 
with PBS and counterstained with DAPI. 
 
2.4. RESULTS 
Construction of conditional targeting vector and generation of REA
d/d 
mice 
To circumvent the lethality we encountered previously in conventional REA knockout 
mice (38),  we employed a Cre-loxP mediated recombination strategy to create conditional REA 
knockout mice. The targeting vector was designed (Fig. 2.1A) to eliminate REA exons 2 through 
6, encoding amino acids 44 to 237, which are required for interaction with ER and repressive 
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activity of ER-target genes (6). Recombinase-responsive elements were introduced, including 
two loxP sequences introduced into REA introns 1 and 6 and an frt-floxed neomycin-resistance 
gene inserted between intron 6 and the 5′-loxP site. These elements were recognized and excised 
by mice expressing Cre and Flp recombinase. Positive ES cells harboring the targeted allele were 
confirmed by Southern blot screening and injected into blastocysts donated from a C57BL/6 
strain and implanted into pseudopregnant female mice (Fig. 2.1B) REA
flox-neo/+ 
chimeric animals 
were mated with Flpe mice (8) for the deletion of neomycin resistance gene cassette in vivo and 
as a result, REA
f/+
 mice were generated. All animals were genotyped by PCR (Fig. 2.1C). To 
ensure the functional integrity of loxP sequences of the targeted allele and to examine the 
efficiency of Cre-loxP mediated deletion, we first tested Cre-mediated REA allele excision in 
vitro.  Uterine stromal cells isolated from REA
f/f 
female mice were infected with adenovirus 
expressing Cre recombinase (AdCre) to delete the REA gene, and REA levels were then 
examined by qRT-PCR and protein immunoblotting.  As shown in Fig. 2.1D, REA levels were 
markedly reduced by AdCre infection, demonstrating functional integrity of LoxP sequences of 
targeted allele.  
Because of our interest in delineating REA actions on fertility, we used mice expressing 
Cre recombinase under control of the progesterone receptor (PR) promoter (PR
cre/+ 
) to delete 
REA in post-embryonic reproductive tissues (44). PR-Cre knockin (PR
cre/+ 
) mice have been 
used successfully to eliminate targeted genes in uterine cells (5, 21, 23, 33). The REA
d/d  
mice 
were finally generated by crossing of the PR
cre/+ 
with REA
f/f 
mice.  Ablation of REA alleles in 
uteri and mammary glands, PR-expressing tissues, was confirmed by genotying PCR (Fig. 2.1E). 
Sequencing analysis of the PCR product from the null allele confirmed PR-driven Cre excised 
REA exons 2 through 6 (Fig. 2.1F).    
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Conditional homozygous (REA
d/d
) female mice are infertile-Analysis of ovulation and 
implantation in the uterus 
Conditional REA homozygous mutants developed to adulthood without gross 
abnormalities, but female homozygous mutant mice were completely infertile. To examine the 
breeding capacity of conditional REA knockout mice, REA
f/f 
and REA
d/d 
females were mated 
with wild-type males and observed for 6 months (Table 2.1). No pups were born from REA
d/d 
females over a 6-month period.  In contrast, REA
d/d 
males displayed normal fertility when mated 
with wild-type females. Because aggressive mating behavior has been reported in ER-knockout 
mice (4, 35), we examined this but, no abnormal sexual behaviors were observed in the mutant 
females and copulatory plugs were detected at the normal frequency, indicating normal mating 
behavior of homozygous REA knockout animals.   
To further explore the cause of infertility, we examined the estrous cycle of REA 
knockout mice as a measure of the integrity of the hypothalamic-pituitary-ovarian reproductive 
axis. Examination of vaginal epithelial cytology demonstrated that females cycled normally (data 
not shown). Next, we investigated the possibility of ovarian dysfunction as a cause of infertility 
in REA
d/d 
females. We first tested whether the ovary of REA
d/d 
was responsive to exogenous 
gonadotropin treatment. As shown in Fig. 2.2A, the number of ovulated eggs was similar to that 
observed in control mice. In addition, histological studies on ovaries isolated from the 
superovulation treatment revealed normal follicle maturation and corpora lutea formation (Fig. 
2.2B and C), further supporting that REA
d/d 
have no obvious ovarian defects. 
We next examined whether blastocysts could properly attach to the uterine luminal 
epithelium to initiate the implantation process.  On the morning of pregnancy day 4-5 (4.5-5.5 
dpc), females were injected by Chicago Blue B dye solution and implantation sites were counted. 
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As shown in Fig. 2.2D and E, no implantation sites were detected in the uteri of REA
d/d 
females, 
while the normal number of implantation sites was observed in the controls. Collectively, these 
results show that, while ovarian function is normal in REA
d/d 
animals, the uterus is completely 
non-receptive to blastocyst implantation.   
 
Uterine decidual response is impaired in REA
d/d 
females 
Successful implantation is followed by proliferation and differentiation of endometrial 
stromal cells into decidual cells (24, 42). We wished to examine whether decidualization, a 
subsequent step after implantation could occur in the uteri of REA
d/d 
animals. We examined 
uterine decidual response by artificial decidual stimulation, which can be induced in the absence 
of embryo implantion by an artificial stimulation to estrogen- and progesterone-primed uteri in 
rodents (26).  REA
f/f
 and REA
d/d 
female animals were ovariectomized and treated with a well-
defined 13 day regimen of exposure to exogenous estrogen and progesterone (See Materials and 
Methods), and oil was infused into the lumen of the left uterine horn to initiate a decidual 
response, with the right horn not manipulated to serve as the control. As shown in Fig. 2.3A, the 
uteri of REA
f/f
 animals exhibited a full decidual response accompanied with a dramatic increase 
in uterine size, as well as characteristic enlargement of decidual cell layers as seen by histology. 
By contrast, the stimulated uterine horn of REA
d/d 
mice failed to undergo a decidual response and 
expression of the decidualization marker genes BMP2, Wnt4, and PRP was significantly lower in 
the uteri of REA
d/d 
animals (Fig. 2.3C).  
To investigate the specific requirement of REA in the uterine stroma for functional and 
morphological decidual reactions, we examined decidualization of uterine stromal cells in vitro 
after exposure to estrogen and progesterone. This well-characterized protocol allowed us to 
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examine the role of REA in the stromal compartment only, as well as enabling strict control of 
Cre-mediated loss of REA by adenoviral infection of cells (24, 42). Primary stromal cells 
isolated from uteri of day 4 REA
f/f
 pregnant mice were infected with either control adenovirus or 
AdCre to excise REA alleles. As shown in Fig. 2.3D and E, AdCre effectively depleted mRNA 
and protein expression of REA and this Cre-mediated REA ablation in stromal cells led to a 
significant reduction of the stromal differentiation markers, prolactin-related protein (PRP), 
Hoxa10 and Hoxa11, whereas the expression of other genes not associated with decidualization 
such as vitamin D receptor (VDR) and GAPDH remained unaltered. These results demonstrate 
that REA is critical factor for successful decidualization both in the uterus in vivo and in uterine 
stromal cells in vitro.  
 
REA
d/d 
females have uterine developmental defects and altered expression of developmental 
genes 
In REA
d/d 
conditional knockout mice, we examined the role of REA in uterine 
development as a critical precursor for successful adult uterine function. The mature uterus is 
comprised of the endometrium and myometrium and development of the endometrial glandular 
epithelium as well as differentiation of endometrial stroma and myometrium from the 
mesenchyme occurs during the neonatal stages after birth and is established by postnatal day 15 
(PND15) (3, 9, 47).  As indicated in Fig. 2.4A, the uterine morphology in mature REA
d/d 
animals 
resembled that of an immature uterus; uterine diameter was dramatically smaller because of 
reduced stroma, and reduced luminal and glandular epithelial volume was evident. Thus, we 
speculated that REA
d/d 
female infertility might be the result of abnormal neonatal uterine 
development and we therefore investigated this. 
29 
 
We collected uteri from different stages of postnatal development and analyzed uterine 
gene expression and histological phenotypes. These evaluations revealed that uteri from REA 
mutants had a morphology similar to that of wild-type animals until PND10, but an abnormal 
uterine phenotype became apparent by PND14 (Fig. 2.4B). To further test whether this abnormal 
uterine development was the result of loss of REA, we examined the REA expression level 
during postnatal development. Genotyping revealed that targeted REA exons were excised by 
PR-driven Cre activity as early as PND5 (Fig. 2.4C).  Depletion of REA mRNA and protein 
expression was also confirmed by qRT-PCR and immunohistochemistry (Fig. 2.4D and E). Of 
note, loss of REA expression was observed in the luminal epithelial beginning at PND5 and REA 
loss was extended to the stromal compartment after PND5 and this loss was observed until 
PND14 (Fig. 2.4E). Consistent with this age- and tissue-specific loss of REA, as shown in Fig. 
2.4F, PR expression was only detected in the epithelial at PND5 with stromal expression 
occuring between PND5 and 10. Therefore, PR-dependent, Cre-mediated loss of REA was well 
correlated with the endogenous PR expression. These results indicate that loss of REA 
expression leads to abnormal uterine development and adversely affects uterine receptivity and 
pregnancy maintenance.   
We also examined the expression of several genes implicated in the regulation of 
postnatal uterine development (9, 14) including bone morphogenic protein 2 (BMP2), Hoxa10, 
epidermal growth factor receptor (EGFR) and hepatocyte growth factor (HGF). As shown in Fig. 
2.5A, expression of these genes was significantly down-regulated in the uteri of REA
d/d 
mice. 
 
Neonatal uterine cell proliferation is decreased and apoptosis is increased in conditional 
homozygous REA mutant mice 
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Our findings of uterine hypoplasia in conditional homozygous REA mutant mice led us 
to investigate cell proliferation and apoptosis. The RNA and protein expression level of the 
cyclin-dependent kinase inhibitor, p21, was significantly increased in the uteri of REA
d/d 
mice 
compared to that of wild-type (Fig. 2.5B and C) and this elevated p21 expression closely 
corresponded with the tissues in which the expression of REA was lost (Fig. 2.5D).  It is 
important to note that increased expression of p21 was detected only in the luminal epithelial 
cells at PND10, but its expression was extended to stroma by PDN14. The pattern of increased 
expression of p21 inversely correlating with the spatial and temporal expression pattern of REA 
(Fig. 2.5D) implies that increased p21 expression in cells lacking REA may result in cell cycle 
arrest and impede normal uterine growth. To examine cellular proliferation, specifically S-phase 
activity of the cell cycle, REA
f/f
 and REA
d/d  
at 5, 10 and 14 days of age were injected with BrdU 
2 h prior to sacrifice and uteri were collected.  As shown in Fig. 2.6A, REA mutant uteri 
exhibited decreased BrdU incorporation indicating that DNA replication was impaired in uteri of 
REA
d/d 
mice.   
We also assessed DNA fragmentation, one of the hallmarks of apoptosis, by TUNEL 
analysis on wild-type and conditional homozygous mutant uteri at 14 days of age. We observed 
markedly increased apoptotic cell death in the REA
d/d 
uterine epithelium and stroma, as 
evidenced by increased fluorescence (Fig. 2.6B). We next examined activation of the apoptosis-
promoting executioner caspase-3 in the wild-type and REA-null uterine cells by 
immunohistochemistry. Because caspase-3 is known to be cleaved from 32 kDa of procaspase-3 
to 18 kDa of caspase-3 to be active, we examined the level of the cleaved form of caspase-3 (39). 
As shown in Fig. 2.6C, positive cells for active caspase-3 were present only in the REA
d/d 
uterine 
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cells. Collectively, these data suggest that the hypoplasia seen in the REA
d/d  
uterus is likely the 
result of a combination of increased G1-S-phase arrest and increased apoptosis.  
 
Conditional REA heterozygous (REA
f/d
) animals show enhanced estrogen responsiveness 
To test the hypothesis that REA function might be gene dose-dependent, we generated 
conditional heterozygous REA animals (REA
f/d
) by crossing REA
d/d 
and wild-type animals and 
first examined the early postnatal uterine development of these animals. As opposed to the 
severely impaired development we observed in uteri of homozygous REA mice, uterine 
morphology and gene expression during postnatal development were found to be similar in 
REA
f/f
 and REA
f/d 
(Fig. 2.S1).  We next performed uterine bioassays to examine the REA dosage 
effect on uterine response to estrogen stimulation. Immature REA
f/f
, REA
f/d 
and REA
d/d 
animals 
were treated for 4 days with E2 or control vehicle, and uterine response was monitored by 
assessing gross morphology, histology, and uterine weight gain. Strikingly, uteri with conditional 
loss of one allele of REA (REA
f/d
) exhibited a very different uterine phenotype from that of 
conditional homozygous mutant (REA
d/d
) mice. The uterine morphology of conditional REA 
heterozygous females was similar to that of the wild type mice (data not shown), however, 
treatment with E2 resulted in markedly larger and fluid-filled uteri (Fig. 2.7A). Of note, the 
lumen area of REA
f/d 
animals was extremely large as compared to wild-type or homozygous 
animals. Also, the estrogen-induced uterine weight increase was significantly greater in REA
f/d 
animals compared to wild type or homozygous animals (Fig. 2.7B). 
To investigate if this exaggerated estrogen-induced uterine weight gain was a result of 
increased uterine cell proliferation, REA
f/f
, REA
f/d 
and REA
d/d 
mice were treated with E2 for 4 
days and then injected with BrdU at 2 h prior to sacrifice. As shown in Fig. 2.7C, the majority of 
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BrdU positive cells was seen in luminal epithelial cells in response to E2 treatment, and the 
proportion of BrdU positive cells was significantly greater in REA
f/d 
animals vs. wild-type or 
homozygous animals. Thus, the data shown in Fig. 2.7 demonstrate that loss of REA results in 
distinct uterine phenotypes dependent on the dosage of the REA gene, such that the REA protein 
level significantly modulates estrogen actions in the uterus.  
 
REA gene dosage impacts uterine gene regulation 
Our in vivo findings demonstrate that loss of one REA allele enhanced estrogen activity 
in uterine tissues, whereas complete loss of both REA alleles impaired uterine cell proliferation 
and increased apoptosis. To determine whether uterine gene expression also depends on REA 
dosage, we monitored the expression of C3 and Lactoferrin since both are genes well known to 
be up-regulated by E2 in the uterus (38). As shown in Fig. 2.8A, estrogen increased C3 and 
Lactoferrin expression much more in the uteri of REA heterozygous animals than in wild type 
floxed animals. 
Because the uteri of conditional heterozygous REA mutant animals treated with E2 were 
filled with large amounts of fluid, we examined whether the genes responsible for uterine water 
imbibition might be hyper-stimulated in the REA conditional heterozygous uteri. It has been 
shown that estrogen stimulates water imbibition in the uterine endometrium, in part, by water 
channel proteins termed aquaporins (AQPs) (17). To date, 13 isoforms of AQPs have been 
identified in mammals and specific AQP isotypes have been shown to be expressed in male and 
female reproductive tissues (15). To test the hypothesis that reduction of REA might enable 
hyper-stimulation of the expression of AQPs in uteri of conditional heterozygous REA mutants, 
we examined the expression of APQs reported to be expressed in the uterus (15). As shown in 
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Fig. 2.8B, among those tested, two AQPs (AQP1 and 2) were down-regulated and three AQPs 
(AQP 3, 4 and 5) were up-regulated by E2 in wild type (REA
f/f
) uteri. Interestingly, AQP4 
stimulation in response to E2 was significantly greater in REA
f/d 
animals vs. wild-type, and was 
greatly reduced in REA
d/d 
uteri, suggesting that the enhanced fluid accumulation in the uteri of 
REA
f/d 
animals might be associated with hyper-stimulation of this aquaporin.  
 
Conditional heterozygous (REA
f/d
) female mice show reduced fertility 
To further investigate if the uterine hyper-responsiveness to estrogen observed in conditional 
heterozygous females impacts reproductive capacity, REA
f/d
 females were mated with wild-type 
males and observed for continuous breeding over 6 months. As presented in Table 2, REA
f/d  
females showed a significant decrease in litter size compared to control mice (6.1±2.5 vs. 
8.9±2.1 pups per litter, p<0.001) and  had fewer numbers of pregnancies (4.3±1.8 vs. 6.4±0.5, 
p<0.001 ) over the 6-month period compared to control mice (Fig. 9). 
 
2.5. DISCUSSION 
Our findings reveal a key role of REA in cell proliferation, survival, and adenogenesis to 
enable proper uterine development and functional activities whereas conditional loss of both 
REA alleles in female mice resulted in infertility due to severely compromised uterine 
development. Perhaps more interestingly, we found that conditional loss of only one REA allele 
resulted in enhanced uterine response to estrogen and increased cell proliferation. This in vivo 
study thus indicates that the correct gene dosage and level of REA are crucial for optimal uterine 
function and that REA serves as a brake to appropriately control estrogen-ER activity.  
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REA/PHB2 is an evolutionarily conserved protein and has increasingly been found to be 
involved in diverse cellular processes including transcription, mitochondrial biogenesis and 
replicative senescence (22, 31, 32, 37).  Our lab previously identified REA in a yeast two-hybrid 
screen using ER as bait and characterized REA as a coregulator that repressed the transcriptional 
activity of the ER (6, 32, 34, 38). In addition to its role as a transcriptional coregulator, REA has 
been shown to exist in a protein complex with prohibitin1 (PHB1) in the mitochondrial inner 
membrane, and the mitochondrial REA/PHB1 complex appears to be important for maintaining 
mitochondrial integrity and biogenesis (29-31, 36, 37).  
To enable insight into the cell- and tissue-specific physiological functions of REA, we 
generated REA conditional knockout animals in which REA function was abrogated only in 
progesterone receptor (PR)-expressing cell lineages. Although PR expression has been detected 
as early as the blastocyst stage, it has been shown that embryonic-derived PR is not required for 
embryonic survival, evidenced by PR knockout mice (13, 26).  As expected, PR-driven Cre 
activity to conditionally remove REA alleles resulted in viable conditional REA knockout 
animals which developed to adulthood.  
 
Uterine developmental defects of homozygous REA knockout animals: Enhanced cell cycle arrest 
and altered uterine adenogenesis 
Normal uterine function is required for fertility, with reproductive health critically 
dependent on proper embryonic and perinatal development, as evidenced by exposure of 
neonates to endocrine disruptors resulting in adult infertility and abnormal estrous cycles (45). 
The uterus begins to develop from the Mullerian duct during embryonic developmental stages 
but it is not completed until after birth. Postnatal uterine development involves massive cell 
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proliferation and differentiation to establish the mature endometrium and myometrium of the 
uterus (3, 9, 14, 47). We observed that the uteri of homozygous REA mutants displayed an 
immature, hypoplastic morphology. This uterine hypoplasia was associated with cell cycle arrest, 
as evidenced by elevated cell cycle inhibitor p21 expression and reduced BrdU uptake, and 
increased apoptosis of uterine epithelial and stromal cells. Loss of REA also resulted in alteration 
of a number of genes implicated in uterine development. Our histological examination of 
postnatal uteri showed a continuous increase in growth and size of the uterus until the age of 14 
days, and this growth was positively correlated with increased levels of growth factors and 
growth factor receptors.  The uterine defects seen in REA knockout animals may be, at least in 
part, mediated through a decreased level of EGFR. Moreover, these uteri contained notably 
fewer endometrial glands. The endometrial glands secrete or transport diverse cellular factors 
such as leukemia inhibitory factor and calcitonin required for the establishment of uterine 
receptivity and nourishing of the developing conceptus. Endometrial gland development from the 
luminal epithelium, termed adenogenesis, involves a series of morphogenic events: budding of 
glandular epithelium (GE) from the luminal epithelium, penetration of stroma by tubes of GE, 
coiling and branching of GE and it is a predominantly postnatal process. In the rodent uterus, 
uterine adenogenesis proceeds from days 9 through 15 (9). Interestingly, the window of time at 
which the altered uterine phenotype develops in REA knockout animals (between ages of 10 to 
14 day) corresponds with the period of endometrial gland development. Of note, our observation 
that depletion of REA expression started from the luminal epithelium and caused cell death 
suggests that the early cell death of luminal epithelial cells in REA knockout animals likely 
contributes to the failure of successful uterine adenogenesis.  
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REA function as a nuclear receptor coregulator  
Our prior in vivo study (38) of conventional REA heterozygous animals (REA
+/-
) along 
with the current studies with conditional tissue-specific REA homozygous (REA
d/d
) and 
conditional REA heterozygous (REA
f/d
)  animals demonstrate that REA is a gene dosage-
dependent coregulator able to profoundly impact steroid receptor function. Female REA 
heterozygous animals showed a greater uterine weight gain in response to E2 and this was due, 
in part, to increased E2-induced cellular proliferation, as evidenced by BrdU incorporation, 
providing strong evidence for REA being a coregulator that represses the activities of estrogen. 
Strikingly, treatment of REA
f/d 
animals with E2 resulted not only in large but also very fluid-
filled uteri. Our findings suggest that the exaggerated fluid accumulation seen in the uteri of 
REA
f/d 
 animals might be through deregulation of aquaporin expression, especially of interest 
because alterations in the expression and regulation of aquaporins have been strongly associated 
with reproductive disorders (15). The hyper-responsiveness to estrogen with 50% reduction of 
REA dosage also influenced female reproductive function and resulted in a subfertility 
phenotype. Both litter size and the frequency of pregnancies was significantly decreased in 
REA
f/d
 animals, implying that tightly regulated estrogen responsiveness of the proper magnitude 
is critical for optimal fertility.    
 
REA is a protein with multiple functions in the uterus 
 It is increasingly appreciated that many cellular proteins have more than one intracellular 
localization and carry out several functions. For example, the estrogen receptor is localized 
primarily in the nucleus but is also found at extranuclear locations, suggested to be cytoplasmic, 
mitochondrial, or membrane associated, and to have effects on gene expression and also on 
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activation of protein kinases and the regulation of energy metabolism (10, 27). Numerous 
connections have also now demonstrated between mitochondrial and nuclear activities, and 
evidence of mitochondrial-nuclear communications, the latter involving transcription factors and 
coactivators that regulate both nuclear and mitochondrial gene expression (40). Indeed, 
mitochondrial biogenesis requires a coordination of expression of nuclear and mitochondrial 
genomes-encoded proteins and therefore cross-talk between these cellular organelles (40).  
Our findings provide evolving understanding of REA as a nuclear transcriptional 
coregulator, and also support a mitochondrial function for REA, as complete deletion of REA 
induced apoptosis and increased caspase-3 activation. Indeed, there is evidence for an REA 
complex with PHB1 in mitochondria (32, 36, 46), PHB1 was shown recently to act like REA to 
repress ERα activity (11). In Xenopus, however, the prohibitins have unique functions and 
Xphb2 cannot substitute for or rescue the activity of Xphb1 as a neural crest specifier in Xenopus 
development (41). 
Our in vivo studies presented here provide new insight into REA functions and assist in 
understanding the key roles of REA in uterine development and maintenance of uterine function 
at maturity, supporting fertility, implantation and uterine decidualization. We have demonstrated 
that REA is clearly a negative regulator of estrogen activity, ensuring optimal physiological 
actions of estrogen by serving as a brake to keep estrogen-stimulated activities in check. Because 
of the impaired cell proliferation and increased apoptosis observed in uteri of conditional 
homozygous REA mice, it is not possible to examine coregulator functions when there is 
complete loss of REA. However, uteri of heterozygous conditional REA mice showed normal 
uterine morphogenesis and development, but enhanced responsiveness to estrogen that resulted 
in a subfertility phenotype, providing new insight into gene dose-dependent physiological roles 
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of REA in development. An important advantage of our REA conditional knockout animals is 
that this mouse model system has enabled examination of the function of REA as a coregulator 
in reproductive tissues and demonstrated both the critical mitochondrial and nuclear activities of 
REA.  
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Figure 2.1. Design of conditional targeting vector and strategy for disruption of the REA 
gene.  
(A) The targeting vector contains positive (NEO), negative (TK) selection markers, two frt 
(indicated as yellow ovals) and two loxP sequences (indicated as triangles). Two loxP sites are 
located in between exons 2 and 6 in the REA gene and two frt sites flank a neomycin resistant 
gene cassette. The REA
flox-frt-neo
 allele was created by homologous recombination in ES cells and 
the REA
flox/+ 
allele was derived from a REA
flox-frt-neo
 allele through in vivo FLP-mediated 
recombination. Finally the PR-Cre mice were used to generate the conditional deletion of the 
REA gene by Cre-mediated excision in the Progesterone Receptor (PR) expressing cell lineage. 
(B) Genomic DNA from ES cell clones was prepared and subjected to Southern blotting after 
XbaI digestion. The location of the 5’ and 3’ probe is indicated in (A). Wild-type allele (22.4 kb) 
and REA
flox-frt-neo
 allele (14 kb and 8.4 kb) are shown. (C) Genomic DNA isolated from mouse 
tail biopsies was genotyped by PCR using primer sets (P1, P2, P3 and P4) designed for 
genotyping PCR shown at left (D) REA protein and mRNA were analyzed by immunobloting or 
qRT-PCR, respectively in mouse uterine stromal cells after adenovirus-mediated Cre (AdCre) 
deletion. mRNA levels were normalized relative to 36B4, and fold change was calculated 
relative to control. Results are the average ± SD of at least three independent experiments. (E) 
Genomic DNA isolated from uterus, mammary gland, liver, kidney and heart was genotyped by 
PCR. (F) PCR product from P1 and P4 primers was purified, sequenced and mapped to the 
mouse genome by UCSC BLAT.  
 
 
 
45 
 
FIGURE 2.2 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Early pregnancy events in REA
d/d 
mice.   
(A) Female mice for each genotype at age 24 day were subjected to superovulatory dose of the 
gonadotropins PMSG and hCG. Oocytes were then extracted from their oviducts and counted.  
(B) Follicular development of the ovary was assessed by histological examination of an ovary 
section after treatment with PMSG only for 48 hr. (C) Formation of Corpora lutea (CL) was 
assessed by histological examination after complete superovulation treatment. Note the presence 
of numerous mature follicles and CL (indicated as arrow) in wild-type and mutant ovaries. (D) 
Representative photographs of uteri from REA
f/f
 and REA
d/d 
at 5.5 dpc.  Arrows indicates sites of 
implantation.  (E) Implantation sites were visually counted by the localized retention of Chicago 
Blue dye  
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FIGURE 2.3 
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Figure 2.3.  REA
d/d 
mice show impaired decidual response in vivo and in vitro.  
(A) Representative gross anatomy and hematoxylin- and eosin-stained uterine sections from 
REA
f/f 
and REA
d/d  
mice after decidual stimulation. The left horn (L) was stimulated, and the 
right horn(R) was not stimulated (see Materials and Methods). Note the dramatic increase in size 
of the left horn after mechanical stimulation. (B) Dectection of REA in the stimulated left horn 
by immunohistochemistry and qRT-PCR. Note high expression of REA in decidual zone. (C) 
Expression level of molecular markers for decidualization measured by qRT-PCR. (D) In vitro 
decidual response of uterine stromal cells. Mouse stromal cells from day 4 pregnant uteri were 
infected by mock or different MOI of AdCre, then REA mRNA and protein levels were analyzed 
by qRT-PCR and immunoblotting, respectively (E).  (F) Molecular markers specific to stromal 
cells were monitored by qRT-PCR.  The data are represented as mean±SD. *, P< 0.05; **, P< 
0.01. 
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FIGURE 2.4 
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Figure 2.4.  REA
d/d 
mice show abnormal uterine growth and maturation.  
(A) Representative hematoxylin- and eosin-stained uterine sections from REA
f/f
 and REA
d/d 
adult 
mice (8 wks).  The amount of stromal (S), endometrial glands (GE) and luminal epithelial tissue 
is minimal in mutant uterus. (B) Neonatal uterine morphology was examined by histological 
examination of uterine section of REA
f/f
 and REA
d/d 
mice at postnatal days 5, 10, 14 and 21 
(PND4, 10, 14 and 21). (C) REA gene is excised in the uteri of REA
d/d 
from as early as age 5 
days. REA deletion was confirmed by conventional genotyping. (D) REA mRNA level was 
monitored by qRT-PCR. Immunohistochemical detection of REA (E) and progesterone receptor 
(PR) (F) from PND 5, 10 and 14 uteri of REA
f/f
 and REA
d/d  
mice. The data are represented as 
mean±SD. *, P< 0.05; **, P< 0.01. 
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FIGURE 2.5 
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Figure 2.5. Uterine developmental gene expression is altered in REA mutant mice.  
(A) mRNA level of molecular markers (BMP2, Hoxa10, EGFR and HGF) implicated in uterine 
development are monitored by qRT-PCR. (B) The cell cycle inhibitor p21 mRNA expression 
levels are elevated in the uterus of REA
d/d  
mice, as measured by qRT-PCR and (C) p21 protein 
levels are elevated in the uterus of REA
d/d  
by immunohistochemistry. (D) Reduction of REA 
expression is correlated with increased p21 expression as measured by immunohistochemistry. 
The data are represented as mean±SD. *, P< 0.05; **, P< 0.01. 
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FIGURE 2.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6.  REA
d/d 
mutants have decreased neonatal uterine cell proliferation and 
increased apoptosis.  
(A) Representative histologic sections of BrdU immunohistochemistry (See Materials and 
Methods) in REA
f/f
 and REA
d/d  
uterus at day 14 mice. Note decreased BrdU incorportation in the 
mutant uterus. (B) Representative fluorescence images of TUNEL staining in uterine sections 
from REA
f/f
 and REA
d/d 
uteri at day14 mice. (C) Immunohistochemical detection of active-
caspase-3 expression in the REA
f/f
 and REA
d/d  
uteri of day14 mice. *, P< 0.05; **, P< 0.01. 
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FIGURE 2.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Uterine growth and cell proliferation in response to estrogen is enhanced in 
REA heterozygous (REA
f/d
) mice 
(A) Gross anatomy and hematoxylin- and eosin-stained uterine sections isolated from vehicle or 
E2 treated REA
f/f
, REA
f/d 
and REA
d/d
 mice. (B) Uterine weight was measured 24 h after the last 
injection and normalized to each animal’s body weight. (C) BrdU immunohistochemistry in uteri 
from REA
f/f
, REA
f/d 
and REA
d/d 
mice treated with E2 for 4 days. Uteri were collected 24 h after 
the last injection and mice were injected intraperitoneally with BrdU 2 h prior to sacrifice. (D) 
BrdU incorporation was represented by mean percentage of BrdU-positive cells/total cells 
monitored in at least 5-6 40X fields. **, P< 0.01. 
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FIGURE 2.8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Uterine estrogen regulated gene expression is enhanced in REA heterozygous 
mutant mice.  
(A) mRNA levels of E2-up-regulated gene expression (complement C3, lactoferrin) monitored 
by qRT-PCR. (B) mRNA levels of Aquaporins known to be expressed in the uterus monitored by 
qRT-PCR. The data are represented as mean±SD. *, P< 0.05; **, P< 0.01. 
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FIGURE 2.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. REA
f/d 
mice show reduced fertility.  
(A) Average of the total numbers of deliveries per dam over 6 months of breeding. (B) Avergae 
numbers of pups per litter. Data are mean±SD. **, P< 0.01. 
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FIGURE 2.10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Model for the relationship between REA gene dosage and ER activity.  
Estrogen signaling was enhanced with 50% reduction of REA level (REA
f/d  
mice), resulting in 
an increased uterine weight gain and enhanced E2-mediated gene expression with estrogen 
treatment. However, complete depletion of REA (REA
d/d  
mice) caused cell cycle arrest and 
apoptosis, leading to the impairment of REA dependent function essential for ER action.   
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TABLE 2.1 
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TABLE 2.2 
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FIGURE 2.S1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.S1. REA
f/d  
mice show normal uterine growth and maturation.  
(A) Neonatal uterine morphology was examined by histological examination of uterine sections 
of REA
f/f
, REA
f/d  
and REA
d/d  
mice at postnatal days 5, 10, 14 and 21 (PND4, 10, 14 and 21). (B) 
mRNA level of BMP2, EGFR and p21 was examined by qRT-PCR. Data are mean±SD.  
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CHAPTER 3 
 
REPRESSOR OF ESTROGEN RECEPTOR ACTIVITY (REA) GENE DOSAGE IS 
CRITICAL FOR MAMMARY GLAND MORPHOGENESIS 
 
 
3.1. ABSTRACT 
 
Estrogen receptor (ER) is a key regulator of mammary epithelial proliferation and ductal 
elongation during postnatal mammary gland development and is also strongly associated with 
breast tumorigenesis. Since ER-mediated transcriptional activity critically depends on 
coregulator proteins, altered coregulator expression has been implicated in breast cancer. Here, 
we investigate the consequences of reduction or loss of function of Repressor of Estrogen 
Receptor Activity (REA) by conditionally deleting REA at different stages of mammary gland 
development and show that REA has essential roles in the morphogenesis of the mammary 
gland. Notably, we find that heterozygosity and nullizygosity for REA result in very different 
mammary gland phenotypes. During puberty, mice homozygous null for REA show severely 
impaired mammary ductal elongation and morphogenesis, whereas mice that are heterozygous 
for REA display accelerated mammary ductal elongation and an increased number of terminal 
end buds. During pregnancy and lactation, mice with homozygous REA gene deletion show a 
loss of lobuloalveolar structures and increased apoptosis of mammary alveolar epithelium, 
leading to significant reduction of body weight of the offspring nursed by females lacking REA, 
whereas body weight of the offspring nursed by females heterozygous for REA was slightly 
higher than that of pups nursed by control mice. We also find that up-regulation of amphiregulin, 
the major paracrine mediator of estrogen-induced ductal morphogenesis in response to estradiol 
(E2), is greater in the mammary gland of REA heterozygous mice compared to control mice. 
Additionally, we demonstrate that reduction of REA level by RNA interference in breast cancer 
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cells enhances E2-mediated gene expression. Taken together, our findings reveal that REA is 
crucial for normal mammary gland development and morphogenesis, and possesses a dosage-
sensitive positive modulatory role in the normal mammary gland and in ERα-positive breast 
cancer cells. 
 
3.2. INTRODUCTION 
The majority of mammary gland development takes place in distinct stages of postnatal 
development. Specifically, puberty, pregnancy, lactation and involution are all tightly controlled 
by the orchestrated action of ovarian steroid hormones and growth factors (5, 19, 28, 43). 
Throughout the recurrent estrous cycles, the epithelial ducts and branches increase, while in 
pregnancy and lactation, alveolar units proliferate and differentiate into milk-secretory cells (5, 
19, 20). The ovarian steroid hormones, estrogen and progesterone, are key mediators of ductal 
morphogenesis and are mitogenic for mammary epithelial cells (1, 19). These physiological 
effects of hormones are mediated through the estrogen receptor (ER) and progesterone receptor 
(PR), both members of the nuclear receptor superfamily of ligand-activated transcription factors 
(24).  
The role of ERα in mammary gland development was largely elucidated through 
knockout of ERα (αERKO) in mice. Mammary glands of αERKO mice were normal before 
puberty; however, after the onset of puberty, a rudimentary ductal structure remained and the 
ducts failed to invade the mammary fat pad, demonstrating that ERα is required for normal 
ductal elongation and outgrowth during puberty (6, 10, 14, 31). Although these animal models 
provided us invaluable insights into the biological function of ERα in mammary gland 
development of virgin mice, exploring the role of ERα in mammary glands beyond puberty was 
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not possible, due to the infertility of αERKO mice. More recently, Khan and colleagues 
developed whey acidic protein (WAP) driven Cre-mediated conditional ERα knockout mice in 
an attempt to address the unresolved role of ERα function in the mammary gland during 
pregnancy and lactation (15). They demonstrated that the ablation of ERα in mammary 
epithelium during late pregnancy and lactation results in a loss of ductal side-branching and 
lobuloalveloar structures, ductal dilation, and decreased the proliferation of alveolar progenitors 
(15). The observations in both conventional and conditional ERα knockout mouse models 
demonstrate that ERα profoundly impacts multiple developmental stages of mammary gland 
development--puberty, pregnancy and lactation.  
It is now well established that the transcriptional activity of ER is modulated by a delicate 
balance between coactivators and corepressors (32, 49). Therefore, changes in the expression 
level of ER coactivators or corepressors can affect the transcriptional activity of the estradiol-ER 
complex and is shown to underlie various disorders of estrogen target tissues (16).  
Repressor of ER activity (REA) was initially identified as an ER selective coregulator 
that repressed the activity of estrogen (36). Our prior heterozygous (REA
+/-
) animals displayed a 
haploinsufficiency phenotype in mammary gland development in which loss of one REA allele 
resulted in enhanced mammary ductal elongation during puberty and increased lobuloalveloar 
development during pregnancy, suggesting that REA is an important modulator of mammary 
gland development (38). Several other lines of study also suggest that levels of REA might be 
associated with breast carcinogenesis. REA expression levels were shown to be positively 
correlated with ER in breast cancer, but inversely correlated with tumor grade (50). Also, the F-
box protein Skp2B, which is often overexpressed in breast cancers, interacts with REA resulting 
in degradation of the REA protein. Additionally, MMTV-Skp2B mice overexpressing Skp2B 
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developed mammary tumors (53). These findings suggest that altered levels of REA might be 
linked to breast tumorigenesis.   
In this study, we sought to dissect the physiological roles of REA at distinct stages of 
mammary gland development. To this end, we generated two types of mammary-specific 
conditional REA knockout animals using a cre-loxP recombination strategy. In order to define 
the role of REA during puberty and after late pregnancy, two different Cre-expressing mice were 
used in this study: progesterone receptor (PR)-Cre knockin mice and whey acidic protein 
(WAP)-Cre transgenic mice, respectively. In our analyses of conditional REA mutant mice, we 
have found that heterozygosity and nullzygosity for REA resulted in opposite mammary gland 
phenotypes. Mice homozygous null for REA show impaired mammary ductal elongation and a 
loss of lobuloalveolar structures, whereas those lacking only one REA allele display an 
enhancement of mammary ductal outgrowth. The phenotypic features of REA heterozygous 
mutant mice are, in part, associated with hyper-stimulation of E2-mediated transcription. Our 
study reveals a critical role for REA gene dosage for normal mammary gland function.  
 
3.3. MATERIALS AND METHODS 
Generation of transgenic REA knockout mice 
The female REA
flox/flox
 mice (Park et al. unpublished_described in Chapter 2) were mated 
with male PR-Cre knock-in mice (51) to generate the REA
flox/flox
 PR
cre
 
/+
 mice. Briefly, female 
homozygous REA-floxed mice (REA
flox/flox
 ) were mated with male homozygous PR-Cre mice 
(PR
cre/cre
) to produce offspring (REA
flox/+
 PR
cre
 
/+
 ) that are heterozygous for both mutations. 
These heterozygous mice (REA
flox/+
 PR
cre
 
/+
 ) were then bred with each other to produce 
conditional REA  homozygous mutant mice that carried two REA floxed alleles and Cre gene. In 
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these mice, Cre-mediated excision of floxed REA led to a null mutation of this gene in PR-
expressing tissues. To generate the REA
flox/+
 WAP-Cre bigenic mouse model, female REA
 flox/flox 
 
mice were mated with male whey acidic protein (WAP)-Cre transgenic mice (30, 54). WAP-Cre 
transgenic mice were generously provided by the laboratory of Dr. Lothar Hennighausen 
(National Institutes of Health, Bethesda, MA). As a means to assess the efficiency of lactation in 
REA
flox/flox
 WAP-Cre dams, the body weight of fostered pups nursed by REA
flox/flox
 WAP-Cre 
dams were compared to the weights of pups nursed by REA
flox/flox
 dams. On postnatal day 2 (P2), 
litter size was normalized to the 6 pups.  
 
Animals, hormone treatment, and tissue collection 
All animals were maintained in accordance with the NIH Guide for Care and Use of 
Laboratory Animals, and all procedures described here were approved by the University of 
Illinois Animal Care and Use Committee. Female mice were ovariectomized at 6 weeks of age 
and rested for 2 weeks for clearance of endogenous steroids. These mice were then injected 
subcutaneously (s.c) with 17β-estradiol (E2) (0.05 µg/g of body weight/day) in 0.1 mL of sesame 
oil for 5 days. For each treatment group, at least seven mice were used at each time point.  
 
Whole-mount staining of mouse mammary glands 
Fourth inguinal mammary glands were excised, spread onto a glass microscope slide, and 
fixed in 4% paraformaldehyde for 2 h at 4°C. The samples were washed with PBS and stained in 
carmine alum solution overnight at room temperature. The samples were then dehydrated using 
stepwise ethanol concentrations and defatted in xylene overnight.  
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Histology and immunostaining and BrdU incorporation assay 
Hematoxylin and eosin staining or immunohistochemistry was performed as previously 
described (25). In brief, the tissues were fixed in 10% buffered formalin phosphate for 24h at 
room temperature, transferred to 70% ethanol, and then embedded in paraffin. 4 µm sections 
were subjected to hematoxylin and eosin staining or immunostaining using antibodies to REA 
(Millipore Co.), PR (DAKO Co.), ER (Novocastra) or Caspase-3(R&D System).   
For 5-bromo-2-deoxyuridine (BrdU) incorporation assay, mice were intraperitoneally 
injected with 30 µg/g of body weight BrdU (BD Biosciences, San Jose, CA) 2h prior to sacrifice. 
Mammary glands were fixed, embedded in paraffin and tissue sections were stained with BrdU 
antibody (BD Biosciences) 
 
Western blot analysis 
Immunoblotting was preformed as previously described (41). The fourth inguinal 
mammary gland was removed at the indicated developmental stage and snap frozen in liquid 
nitrogen. The protein lysates were prepared using ice-cold lysis buffer (25 mM Tris-HCl pH 7.4, 
150 mM NaCl, 1% NP-40, 1%  sodium deoxycholate, 1% SDS) supplemented with protease 
inhibitors (complete EDTA free; Roche, Indianapolis, IN) and phosphatase inhibitors (Phopho-
stop; Roche). Protein concentrations were determined by the BCA protein assay system (Pierce, 
Rockford, IL). Proteins (20-50 µg) were separated on SDS-PAGE gels, transferred on 
nitrocellulose membranes and subjected to immunoblotting with anti-REA (Millipore, Co., 
Billerica, MA), anti-phospho-STAT5 (Cell Signaling Technology) and anti-ERK2 (SantaCruz 
Biotechnology).  
 
66 
 
RNA isolation and real-time PCR 
Total RNA was isolated from mammary glands at the indicated developmental stage 
using Trizol
 
Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
One microgram of total RNA was reverse transcribed
 
and analyzed by real-time PCR as 
described previously (41).  
 
TUNEL staining 
Apoptosis was detected by using the In Situ Cell Death Detection Kit (Roche Applied 
Science) according to the manufacturer’s protocol.  Briefly, deparaffinized and rehydrated 
sections were incubated at 37°C for 15 min with 20 µg/mL of proteinaseK in 10 mM Tris-HCl 
(pH 7.6). Sections were washed twice with PBS and incubated for 1 h at 37°C with TUNEL 
reaction mixture in a humidified chamber.  After the incubation, sections were rinsed three times 
with PBS and counterstained with DAPI. 
 
Cell culture and RNA interference 
 MCF-7 cells were grown in MEM (Sigma-Aldrich) supplemented with 5% calf serum 
(HyClone). At 6 days before E2 treatment, cells were switched to phenol red-free MEM 
containing 5% charcoal-dextran-treated calf serum. Medium was changed on 2 and 4 of culture 
and cells were then seeded in 60 mm dishes to be 60-70% confluent upon transfection. siRNA 
targeting firefly luciferase (siCONTROL Non-targeting siRNA #2, Dharmacon) or REA were 
transfected in OPTI-MEM media (Invitrogen) using Dharmafect (Dharmacon) to a final 
concentration of 50 nM.  After 48 h of siRNA transfection, cells were treated for 4 h with 10 nM 
E2.  
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3.4. RESULTS 
REA is widely expressed in the developing mammary gland 
To investigate the biological function of REA on mammary gland development and 
morphogenesis, we generated REA conditional knockout mice by Cre-loxP recombination in 
which REA function was abrogated only in progesterone receptor (PR)-expressing mammary 
cells. We first examined the expression pattern of REA during mammary gland development. As 
shown in Fig. 3.1, almost all mammary cells were positive for REA expression. However, PR 
was only expressed in body cells and a subgroup of luminal epithelial cells during puberty, thus 
restricting loss of REA expression to the body cells within the terminal end buds (TEBs) and to a 
subgroup of luminal epithelial cells in the pubertal gland (Fig. 3.1). Genotyping confirmed the 
ablation of REA alleles in mammary glands of virgin mice (data not shown). As we previously 
found that REA
f/f
 PR
Cre/+ 
mice were infertile (Park et al, unpublished), PR-Cre-mediated REA 
knockout animals were only used in order to examine the role of REA in mammary gland 
development prior to pregnancy. Of particular note, the number of mammary cells expressing PR 
was previously shown to be significantly reduced during pregnancy, lactation and involution 
(23). We also confirmed very low PR expression at lactation day 14 by immunohistochemistry 
(Fig. 3.1). Additionally, we assessed the pattern of ERα expression because we are particularly 
interested in how REA impacts ERα signaling during mammary gland development. As shown 
in Fig. 3.1, the expression pattern for ERα was similar to that observed for PR in the pubertal 
mammary gland, but ERα expression was quite high during late lactation period (lactation day 
14).  
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Mammary ductal outgrowth is impaired in mice lacking both alleles of REA, but is enhanced in 
mice lacking only one allele of REA 
ERα signaling is known to direct ductal elongation and branching, which occurs through 
the proliferation of TEBs (26). We wished to determine the contribution of REA to pubertal 
mammary gland development. To this end, we analyzed the status of ductal elongation and 
branching in the virgin mammary glands of REA
f/f
, REA
f/+
PR
Cre/+
 and REA
f/+
PR
Cre/+
 mice. Since 
normal ductal elongation begins around 4 weeks of age and ends by 10 weeks (21), number four 
inguinal glands were isolated and whole mounted at 4, 6, and 8 weeks of age. To assess the 
extent of ductal outgrowth, the distance from the lymph node to the end of the longest extended 
duct was measured. Although the gross morphology of glands from 4 weeks of age was similar 
in REA
f/f
, REA
f/+
PR
Cre/+
 and REA
f/+
PR
Cre/+
 mice (data not shown), differences in mammary 
ductal outgrowth of pubertal period mice (6-8 weeks of age) were apparent. As shown in Fig. 
3.2A, mammary ductal morphogenesis was severely impaired in glands from mice homozygous 
null for REA. More interestingly, in comparison with glands from REA
f/f
 mice, ductal 
morphogenesis was accelerated in glands from REA
f/+
PR
Cre/+
 mice, as evidenced by longer 
ductal length in the absence of only one allele of REA. Similarly, the number of terminal end 
buds was significantly higher in glands from REA
f/+
PR
Cre/+
 mice (19.8±4.0, n=7) than in glands 
from REA
f/f
 mice (9.3±1.3, n=7) (P<0.01). Although the number of terminal end buds declined in 
both genotypes at 8 weeks of age, it was still significantly higher in glands from REA
f/+
PR
Cre/+
 
mice (12.8±2.1, n=8) than in glands from REA
f/f
 mice (8.3±2.5, n=7) (P<0.01). After puberty, 
mice homozygous null for REA displayed even more severe defects in mammary morphogenesis 
(24 weeks of age). The mammary ductal network of REA
f/f
 PR
Cre/+
 mice had barely invaded the 
fat pad, and side branching was almost fully absent, while control REA
f/f
 females exhibited 
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extensive branching and normal fat pad invasion (data not shown). These observations that 
mammary ductal outgrowth is accelerated by loss of one allele of REA, but inhibited by loss of 
both alleles, suggest that normal mammary gland development and morphogenesis is sensitive to 
REA gene dosage. 
 
Conditional deletion of the REA gene in the mammary gland during pregnancy and lactation 
Since REA
f/f
 PR
Cre/+
 females are infertile, we were unable to explore the physiological 
function of REA during pregnancy and lactation with REA
f/f
 PR
Cre/+
 mice. Thus, REA 
conditional knockout mice that carry a Whey Acidic Protein (WAP)-Cre transgene and REA 
floxed alleles (REA
f/f 
WAP-Cre) were generated (Fig. 3.3A) (54). In the mammary gland, the 
WAP-Cre transgene was shown to be expressed exclusively in mammary epithelium during late 
pregnancy and through lactation and is activated by prolactin and Stat5 signaling (7, 11, 29). 
Because WAP is expressed in differentiating mammary epithelial cells, the use of the WAP-Cre 
transgenic mice allowed us to delete the REA gene only in differentiated cells and to examine 
whether REA is needed for the maintenance of differentiated mammary epithelium after it has 
undergone pregnancy-induced proliferation and differentiation (11, 45). As shown in Fig. 3.3B, 
ablation of the REA alleles was mammary gland specific among tested organs as examined by 
genotyping.  Using qRT-PCR and immunoblotting, we also confirmed the deletion of REA in 
REA
f/f 
WAP-Cre mammary tissues from late pregnancy (P18) to lactation (L2 and L14) (Fig. 
3.3C-D). As shown in Fig. 3.3E, uniform REA protein expression was observed in REA
f/f 
epithelium at L14, while about half of the epithelial cells were devoid of REA in REA
f/f 
WAP-
Cre mice.  
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Pups nursed by REA
f/f
 WAP-Cre
 
females displayed greatly reduced weight gain 
Although the REA
f/f 
WAP-Cre dams could support their litters during lactation, REA 
deficiency in the epithelium of the mammary glands profoundly impaired the normal growth of 
the offspring. All litters born to REA
f/f 
WAP-Cre dams survived until the time of the weaning 
(postnatal day 21) but these pups exhibited low body weights (Fig. 3.4A and B). To carefully 
examine the time line of lactation failure of the REA
f/f 
WAP-Cre mice, pup body weights were 
measured throughout postnatal development (P2-P20). On P2, the litter size was normalized to 
six pups. As shown in Fig. 3.4C and Table 3.1, the average body weight of 2-day-old pups 
nursed by REA
f/f 
WAP-Cre dam was about 6% less than that of pups from REA
f/f 
females (1.28 g 
versus 1.36 g). The growth retardation of the pups was even more severe after day 7 (lactation 
day 7), with the average body weight of pups nursed by an REA
f/f 
WAP-Cre mother being about 
34% less than that of pups nursed by control mice. Statistical analysis of this data is summarized 
in Table 3.1.  
 
REA is required for the maintenance of differentiated lobuloalveloar structure 
During pregnancy and lactation, marked changes occur in the mammary gland. Initial 
changes observed during pregnancy include an increase of ductal branching and formation of 
alveolar buds, and these alveolar buds progressively differentiate into individual alveoli that 
ultimately become milk-producing lobules during the second half of pregnancy (43). Following 
parturition, the secretory lobuloalveolar structures become more apparent with extended luminal 
space (2). To determine the impact of conditional REA ablation on mammary gland 
development, we examined the mammary gland morphology from REA
f/f
 and REA
f/f 
WAP-Cre 
females at multiple stages of pregnancy and lactation by hematoxylin-eosin staining.  As shown 
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in Fig. 3.4C, the number of alveoli from the REA
f/f
 mammary gland was greatly increased from 
day 8 (P8) to day 18 pregnancy (P18). Proteins (stained by purple/pink in hematoxylin and eosin-
stained sections) and lipids begin to appear in the alveolar lumen and the alveolar epithelial cells, 
respectively. Fully differentiated alveoli are observed at L2 and are expanded further until the 
lactation is complete (Fig. 3.4C). Morphological changes in the REA
f/f
 WAP-Cre mammary 
gland were similar to control mice until L2 (Fig. 3.4C). However, in the case of the REA
f/f
 WAP-
Cre mammary gland, at lactation day 14 (L14), the alveoli begin to collapse and adipocytes 
begin to reappear in the mammary gland (Fig. 3.4C). The epithelium also appears very 
disorganized in the REA
f/f
 WAP-Cre mammary glands. After weaning of the pups, the mammary 
gland goes through a process of involution, requiring both apoptosis and tissue remodeling (42, 
43). Interestingly, the histology of the mammary gland between REA
f/f
 and REA
f/f
 WAP-Cre 
during involution was very different. As shown in Fig. 3.4C, after 3 days of weaning, the REA
f/f
 
mammary glands still maintained the secretory alveolar structures with apoptotic bodies visible 
in luminal spaces, while most of the alveoli in REA
f/f
 WAP-Cre mice were already collapsed. 
Thus involution seems to be dramatically accelerated in REA
f/f
 WAP-Cre mice. These 
observations indicate that REA is required for normal lobuloalveolar development and 
maintenance of differentiated lobuloalveolar structures during pregnancy, lactation and 
involution.  
 
REA is required for Stat5-mediated gene expression, lactose synthesis and lipid secretion 
The observed growth retardation of offspring nursed by conditional REA knockout mice 
and abnormal lobuloalveolar structures in the mammary gland of mice lacking REA led us to 
investigate the content of milk produced by REA
f/f
 WAP-Cre mice. Mouse milk contains about 
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12% protein (several casein proteins, α-lactalbumin, whey acidic protein, lactoferrin, secretory 
immunoglobulin A, and others), 30% lipid, and 5% lactose (2). We first examined the content of 
milk proteins in the REA
f/f
 WAP-Cre mice at different stages of pregnancy and lactation. As 
shown in Fig. 3.4D, mRNA expression for major milk proteins, caseins and whey acidic protein 
(WAP), was dramatically up-regulated as lactation progressed in the control mice. However, 
expression of these genes was significantly dampened in the mammary gland of REA
f/f
 WAP-
Cre mice. We also found that expression of α-lactalbumin, an essential and limiting cofactor for 
lactose synthase (43) and butyrophilin, known to be involved in milk lipid secretion (43, 44), 
were greatly reduced in the mammary gland of REA
f/f
 and REA
f/f
 WAP-Cre mice (Fig. 3.5C). Of 
note, the significant reduction of the expression of these genes was observed at lactation day 14 
(L14) which is approximately the same time we observed alveoli collapse in the conditional 
knockout mammary glands.  
Because these milk protein genes have been shown to be regulated by prolactin (PRL) via 
phophorylation of Stat5 (30, 39), we wished to determine if a diminished activation of Stat5 in 
the mammary gland of REA
f/f
 WAP-Cre mice might be responsible for the compromised milk 
protein gene expression. To this end, levels of phosphorylated Stat5 were examined in the 
mammary gland of REA
f/f
 and REA
f/f
 WAP-Cre at L14 by immunoblotting. As shown in Fig. 
3.4E, phosphorylation of Stat5 in the REA
f/f
 WAP-Cre at L14 was markedly reduced compared 
to REA
f/f
 mice. These data imply that deficiency of REA in the mammary gland contributes to an 
altered mammary morphogenesis, leading to compromised milk production. 
 
Pups nursed by REA
f/+
WAP-Cre
 
females displayed increased weight gain  
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Since we observed accelerated mammary ductal outgrowth in the REA
f/+
PR
Cre/+
 
mammary gland during pubertal period, we wished to examine the impact of loss of only one 
allele of REA on mammary gland development during pregnancy and lactation. To this end, pups 
body weight nursed by REA
f/+
WAP-Cre
 
females were measured and the gene expression 
involved in milk production was examined. As shown in Fig. 3.5A, the average body weight of 
5-day-old pups nursed by REA
f/+
WAP-Cre
 
dam was about 16% more than that of pups from 
REA
f/f
 females (2.66 g versus 3.09 g). Similarly, the average body weights of 7-, 9-, 11-, 13 and 
14-day-old pups fostered by REA
f/+
WAP-Cre females were 18% (3.64g versus. 4.32 g), 13% 
(4.77 g versus 5.42 g), 9% (5.89g versus. 6.46 g), 7% (6.92 g versus 7.47 g) and 8% (7.21 g 
versus 7.82 g) more than that of pups from control mice. Consistent with this body weight 
results, stimulation of the genes involved in milk production (caseins, α-lactalbumine, 
butyrophilin, and Elf-5) was significantly greater in the mammary gland of REA
f/+
WAP-Cre 
females (Fig. 3.5B), but these differences were apparent only in early lactation periods (lactation 
day 2 and 5). Statistical analysis of this data is summarized in Table 3.1.  
 
Complete REA loss of function induces apoptosis of differentiated mammary epithelial cells 
Because the REA
f/f
 WAP-Cre mice displayed earlier alveoli collapse in the mammary 
gland, we wished to determine whether mammary epithelial cells in REA
f/f
 WAP-Cre mice had a 
higher apoptotic rate.  To do this, we examined expression of mRNA for cell cycle-regulatory 
proteins, p21, p27 and p53 by qRT-PCR. As shown in Fig. 3.6A, the cyclin-dependent kinase 
inhibitor, p21, was significantly increased in the mammary glands of REA
f/f
 WAP-Cre compared 
to that of wild-type, while expression of the two other genes, p27 and p53, was not affected by 
REA deletion. In order to examine the extent of apoptosis in the wild-type and conditional REA 
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mutant, TUNEL analysis was used as a measurement of DNA fragmentation on mammary 
glands obtained from both REA
f/f
 and REA
f/f
 WAP-Cre mice at L14. We observed markedly 
increased apoptotic cell death in the REA
f/f
 WAP-Cre mammary, as evidenced by increased 
fluorescence (Fig. 3.6B).  Similarly, we also examined the activation of the apoptosis-promoting 
executioner, caspase-3, in the wild-type and REA-null mammary glands by 
immunohistochemistry. As shown in Fig. 3.6C, positive cells for active caspase-3 were present 
only in the REA
f/f
 WAP-Cre mammary glands. Of note, most of the apoptotic bodies were 
present in luminal spaces. Taken together, these data indicate that loss of REA during late 
pregnancy and lactation results in an inability to maintain the differentiated mammary alveolar 
structure, possibly due to a combination of increase in G1-S-phase arrest and increased 
apoptosis.  
 
Reduction of REA enhanced estrogen responsiveness in the mouse mammary gland 
 Since we observed accelerated mammary ductal outgrowth in the absence of one allele of 
REA and because estrogen is known to be critical for this process, we hypothesized that REA 
represses estrogen-mediated mammary ductal outgrowth. Additionally, we found that the 
differences in mammary ductal outgrowth between REA
f/f
 and REA
f/+
PR
Cre/+
 mice were very 
apparent particularly during pubertal period (6-8 weeks of age). To test our hypothesis, we 
ovarictomized mice at 6 weeks of age and treated with estradiol (E2) or control vehicle for 5 
days. As shown in Fig. 3.7A, ovariectomy at 6 weeks of age causes TEB regression and halts 
ductal elongation while treatment with E2 resumes TEB formation and ductal elongation.  In an 
attempt to identify the gene responsible for accelerated mammary ductal outgrowth seen in the 
REA
f/+
PR
Cre/+
 mice, we examined the expression level of amphiregulin in the mammary gland 
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treated with E2 because amphiregulin is the major paracrine mediator of ductal outgrowth and 
directly regulated by E2 (8, 28). As shown in Fig. 3.7B, up-regulation of amphiregulin in 
response to E2 was greater in the mammary gland of REA heterozygous mice, suggesting that 
accelerated mammary outgrowth in the mammary gland of REA
f/+
PR
Cre/+
 animals is, in part, 
associated with hyper-stimulation of amphiregulin. 
  
3.5. DISCUSSION 
Our conditional REA knockout models, devoid of either one or both REA alleles, have 
uncovered a critical relationship between gene dosage of REA and mammary gland development 
and functional activities. Complete loss of both REA alleles severely impedes mammary ductal 
morphogenesis and maintenance of differentiated lobuloalveloar structures, whereas a reduction 
of REA dosage via single allele deletion enhances mammary morphogenesis. In the present 
study, we have demonstrated that the consequences of complete REA loss result in increased 
apoptosis of mammary epithelial cells as evidenced by DNA fragmentation and caspase 
activation. Loss of a single REA allele results in accelerated ductal morphogenesis and is at least 
partially due to enhanced estrogen responsiveness.   
 
Repressor of Estrogen Receptor Activity (REA), also known as prohibitin2 (PHB2) is an 
evolutionarily conserved protein with established roles in multiple, essential cellular processes 
including transcription, mitochondrial biogenesis and replicative senescence (4, 9, 12, 18, 27, 33, 
35, 38, 40, 41). Previous reports suggest that REA is a multifunctional protein, located in several 
sub-cellular regions—nucleus, plasma membrane, and mitochondria (35). Although the 
molecular function of REA is still not completely understood, REA activity in mitochondrial 
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functions has been considered to be critically linked to cell proliferation and mitochondrial 
morphogenesis (33-35). Our findings in animals with conditional deletion of both REA alleles 
agree with previously observed embryonic lethality of conventional REA knockout animals (41) 
and in vitro studies that have shown that the deletion of REA impaired proliferation of mouse 
embryonic fibroblasts (MEFs) (33). In particular, Langer and colleagues recently have shown 
that REA controls cell proliferation and apoptosis by regulating small dynamin-like GTPase 
OPA1 (optic atrophy 1), a component of the mitochondrial fusion machinery (33). Silencing of 
REA resulted in a loss of OPA1 and altered cristae formation, which was restored by expression 
of a long form of OPA1(33). Consistent with these findings, we also observed a loss of long 
form of OPA1 in the mammary glands from REA
f/f
 WAP-Cre mice (data not shown). The 
phenotypic outcomes of complete loss of both REA alleles in the mammary gland- cell cycle 
arrest and increased apoptosis of mammary cells- could be partially associated with defects of 
mitochondrial functions of REA.  
Female mice lacking only one allele of REA had a mammary gland phenotype very 
different from that of homozygous null REA mice. In virgin mice, 50% reduction of REA dosage 
resulted in accelerated mammary ductal elongation and an increased number of terminal end 
buds in a specific pubertal period (6-8 weeks of age), whereas the morphological differences 
from mammary glands at 15 weeks of age were not apparent. Although both estrogen and 
progesterone are key mediator of ductal morphogenesis, estrogen is generally considered to be 
responsible for ductal outgrowth and minor-branching, while progesterone leads to tertiary 
branching and alveolar development (1, 13, 19). Our observations with accelerated ductal 
outgrowth in the pubertal mammary gland suggest that REA might profoundly impact estrogen-
mediated ductal morphogenesis. Furthermore, in an attempt to identify genes that are responsible 
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for this accelerated ductal elongation and are also regulated by estrogen, we ovariectomized 
pubertal mice (6 weeks of age) and treated them with estradiol (E2) for 5 days. We found that 
up-regulation of amphiregulin, the major paracrine mediator of estrogen-induced ductal 
morphogenesis, was greater in the mammary glands of REA heterozygous mice compared to 
control mice. In addition to this hyper-stimulation of amphiregulin by E2 in the absence of one 
allele of REA, enhanced ER transcriptional activity was also demonstrated by our prior in vivo 
ERE-luciferase activity assay in conventional REA heterozygous animals (REA
+/-
) where ER 
transcriptional activity was much greater in REA
+/-
/ERE-Luc mice than in WT/ERE-Luc mice 
(38).  Thus, an important future goal in investigating the role of REA in mammary ductal 
morphogenesis will be to identify the specific downstream targets that are altered in the 
mammary gland of REA heterozygous mice by expression profiling.  
 
The role of ERα in mammary gland development during pregnancy and lactation was 
recently investigated by generation of conditional ERα knockout mice by use of WAP-Cre 
transgenic mice (15). Because conventional ERα knockout mice (αERKO) were infertile, it was 
not possible to explore the role of ERα beyond puberty. Conditional ERα knockout mice also 
showed that ERα ablation in mammary epithelium during late pregnancy and throughout 
lactation resulted in a loss of ductal side-branching and lobuloalvelolar structures, ductal dilation, 
and decreased proliferation of alveolar progenitors (15). Both of these conventional and 
conditional ERα knockout mouse models demonstrate that ERα profoundly impacts pubertal as 
well as pregnant and lactating mammary gland development.  
Our analysis of mice that are heterozygous for REA only during late pregnancy and 
lactation (REA
f/+
WAP-Cre) showed that the average body weight of the offspring nursed by 
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REA
f/+
WAP-Cre mice was higher than that of pups nursed by control mice. Consistent with 
these body weight results, stimulation of the genes involved in milk production (caseins, α-
lactalbumine, butyrophilin, and Elf-5) was significantly greater in the mammary gland of 
REA
f/+
WAP-Cre females. However, distinct morphological differences between REA
f/f 
and  
REA
f/+
WAP-Cre mice throughout pregnancy and lactation were not observed (data not shown), 
whereas our prior conventional REA heterozygous animals (REA
+/-
) displayed histologically 
enhanced pregnancy-associated ductal and alveolar morphogenesis (38). The phenotypic 
differences between conditional and conventional REA heterozygous animals were possibly due 
to the differences of time- and cell-specific inactivation of one REA allele because the use of 
WAP-Cre transgenic mice allowed us to delete one allele only after mammary epithelium 
differentiation is complete and only in alveolar epithelial cells. Additionally, it is not clear 
whether observed phenotypic outcomes from REA
f/+
WAP-Cre mice are also associated with 
altered estrogen signaling during pregnancy and lactation, because estrogen levels are known to 
be declined sharply after birth because of the loss of the corpus luteum. We also could not rule 
out the possibility that REA might enhance ER activities by estrogen-independent pathways 
during pregnancy and lactation.  
 
Since ER-mediated transcriptional activity critically depends on coregulator proteins, 
altered coregulator expression has been implicated in breast cancer (17, 37). For example, one of 
well characterized coactivator protein for ERα, AIB-1/SRC-3, is shown to be overexpressed in 
60% of primary breast tumors and transgenic mice in which AIB-1 is overexpressed in the 
mammary gland resulted in development of malignant mammary tumors (3, 17, 52). There are 
also several lines of studies suggesting that REA might be associated with breast carcinogenesis. 
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REA expression levels were shown to be positively correlated with ER in breast cancer, but 
inversely correlated with tumor grade (37). More recently, the F-box protein Skp2B, which is 
often overexpressed in breast cancers, was shown to interact with REA resulting in degradation 
of the REA protein (53). In the mammary gland of MMTV-Skp2B mice in which Skp2B is 
overexpressed, REA levels were found to be low and these mice develop mammary tumors (53). 
These findings suggest that altered levels of REA might be linked to breast tumorigenesis.  
In the present study, we found that the number of terminal end buds (TEBs) was 
significantly increased in the mammary gland of REA heterozygous mice compared to that of 
control mice. TEBs are the structures in the mouse mammary gland that give rise to malignant 
mammary tumor upon exposure to a chemical carcinogen (22, 46, 48). Similar structures in a 
human breast, called terminal ductal lobular unit 1 (TDLU1), also known to be the sites of breast 
cancer initiation in women (47). Thus, it is possible that reduced level of REA in the mammary 
gland might enhance the susceptibility to chemically induced mammary tumorigenesis. Of note, 
enhancement of estrogen responsiveness seen in the mammary gland of heterozygous animals 
was also observed in ERα positive human breast cancer cells, evidenced by hyper-stimulation of 
E2-mediated up-regulated genes (pS2, PgR, GREB1, and SERPINB9) (data not shown). These 
findings suggest that some functional activities of REA are common in both the mouse 
mammary gland and breast cancer and REA might possess a potential role in human breast 
cancer. 
 
In summary, our animal models with conditional loss of both or one REA allele provide 
the first in vivo evidence that REA is a multifunctional protein with a gene dosage-sensitive 
modulatory role in mammary gland development.  
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3.7. FIGURES, TABLE AND LEGENDS           
 
FIGURE 3.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. REA is expressed in the developing mammary gland. 
Immunohistochemical detection of ER, PR and REA in virgin terminal end buds (TEBs) (6 
weeks) and lactating alveoli (lactation day 14). The scale bars represent 200 µm. 
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FIGURE 3.2 
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Figure 3.2. Mammary ductal outgrowth is faster in mutant mice heterozygous for REA, but 
severely impaired in mice homozygous null for REA.  
(A) Whole-mount staining of the number 4 inguinal mammary glands from REA
f/f
 , REA
f/+
 
PR
Cre/+ 
and REA
f/f
 PR
Cre/+ 
virgin mice at 6, 8 and 15 weeks of age. (B) Ductal length of the 
mammary glands at 6 and 8 weeks of age. Distance from the lymph node to the end of the 
longest extended duct was measured. The line in box plots represents the median length 
measured from eight mammary glands. (C) The number of terminal end buds per mammary 
gland was counted in wholemounts of number 4 inguinal glands at 6 weeks of age. *, P< 0.05; 
**, P< 0.01.  
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FIGURE 3.3 
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Figure 3.3. Conditional knockout of the REA gene during pregnancy and lactation.    
(A) Schematic diagrams of the REA gene targeting strategy.  (B) Genomic DNA isolated from 
uterus, ovary, mammary gland, liver, kidney and heart was genotyped by PCR. (C) REA mRNA 
and protein (D) were analyzed by qRT-PCR or immunoblotting, respectively in mammary 
tissues at different stages of pregnancy (P) and lactation (L). The data are represented as 
mean±SD. (E) Immunohistochemical detection of REA in REA
f/f
 and REA
f/f
 WAP-Cre 
mammary glands at L14. *, P< 0.05; **, P< 0.01.  
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FIGURE 3.4 
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Figure 3.4. REA is required for the maintenance of differentiated lobuloalveloar structure. 
(A) Representative photograph of pups nursed for 20 days by REA
f/f
  or REA
f/f
  WAP-Cre mice. 
(B) Box plots of pups body weight nursed by REA
f/f
 or REA
f/f
  WAP-Cre mice during postnatal 
development. Horizontal lines in the boxes represent the first, second (the median), and third 
quartiles. (C) Representative hematoxylin- and eosin-stained mammary gland sections from 
REA
f/f
 and REA
f/f
 WAP-Cre at different stages of pregnancy (P), lactation (L) and involution (I). 
Magnification, ×40.  (D) qRT-PCR analysis of genes involved in milk protein expression 
(casein-α, casein-β, casein-κ and whey acidic protein (WAP)), lactose synthesis (α-lactalbumin) 
and milk lipid secretion (butyrophilin) at different stages of pregnancy (day 8 and 18) and 
lactation (day 2, 14 and 19). The data are represented as mean±SD. (E) Mammary gland lysates 
were analyzed by immunoblotting for REA and phosphor-Stat5. ERK2 served as a loading 
control. *, P< 0.05; **, P< 0.01.  
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FIGURE 3.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  Body weight gain of pups nursed by REA
f/+
WAP-Cre
 
females was increased 
and correlated with increased milk-related gene expression.  
(A) Box plots of pups body weight nursed by REA
f/f
  or REA
f/+
WAP-Cre mice during postnatal 
development. Horizontal lines in the boxes represent the first, second (the median), and third 
quartiles. (B) mRNA level of REA, casein-β, casein-κ , α-lactalbumin, butyrophilin and Elf-5 
was examined by qRT-PCR at different stages of pregnancy (day 18) and lactation (day 2, 5,9 
and 14). The data are represented as mean±SD. *, P< 0.05; **, P< 0.01.  
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FIGURE 3.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.  REA
f/f
 WAP-Cre
 
mutants have increased apoptosis of mammary epithelium. 
(A) The cell cycle inhibitor p21levels are elevated in the mammary gland of REA
f/f 
WAP-Cre 
mice, as measured by qRT-PCR. The data are represented as mean±SD.
 
(B) Representative 
fluorescence images of TUNEL staining in mammary gland sections from REA
f/f
 and REA
f/f
 
WAP-Cre
 
mammary glands of lactation day14 mice. (C) Immunohistochemical detection of 
active caspase-3 expression in the REA
f/f
 and REA
f/f
 WAP-Cre mammary glands of lactation 
day14 mice. *, P< 0.05; **, P< 0.01.  
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FIGURE 3.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Reduction of REA enhances E2-mediated transcription in mouse mammary 
gland. 
(A) Whole-mount staining of mammary glands from vehicle (oil) or estradiol-treated REA
f/f
 and 
REA
f/+
 PR
Cre/+ 
and REA
f/f
 PR
Cre/+ 
mice. 6 week old mice were ovariectomized, allowed to rest 
for 2 weeks, then treated with either oil or estradiol. (B) mRNA level of amphiregulin (AREG) 
was measured by qRT-PCR. Data are mean±SD. *, P< 0.05; **, P< 0.01. 
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